View Filing Data

Print Document View Excel Document

DEI Document - USD ($)	12 Months Ended
DEI Document - USD ($)	Dec. 31, 2017	Jan. 31, 2018	Jun. 30, 2017
Entity Information [Line Items]
Entity Registrant Name	ICU MEDICAL INC/DE
Entity Central Index Key	0000883984
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		20,239,458
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Entity Well-Known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 3,127,790,010

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 290,072,000	$ 445,082,000
Short-term investment securities	10,061,000	0
TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES	300,133,000	445,082,000
Accounts receivable, net of allowance for doubtful accounts of $2,447 at December 31, 2017 and $1,073 at December 31, 2016	112,696,000	56,161,000
Inventories	288,657,000	49,264,000
Prepaid income taxes	10,594,000	11,235,000
Prepaid expenses and other current assets	41,286,000	7,355,000
Due from Related Parties, Current	98,807,000	0
Assets Held-for-sale	12,489,000	0
Total current assets	864,662,000	569,097,000
PROPERTY AND EQUIPMENT, net	398,684,000	85,696,000
LONG-TERM INVESTMENT SECURITIES	14,579,000	0
GOODWILL	12,357,000	5,577,000
INTANGIBLE ASSETS, net	143,753,000	22,383,000
DEFERRED INCOME TAXES	24,775,000	21,935,000
Other Assets	38,141,000	0
TOTAL ASSETS	1,496,951,000	704,688,000
CURRENT LIABILITIES:
Accounts payable	78,228,000	14,641,000
Accrued liabilities	132,064,000	25,896,000
Total current liabilities	210,292,000	40,537,000
Contingent Earn-out Liability	27,000,000	0
OTHER LONG-TERM LIABILITIES	55,326,000	1,107,000
DEFERRED INCOME TAXES	1,487,000	1,370,000
INCOME TAX LIABILITY	4,592,000	1,519,000
COMMITMENTS AND CONTINGENCIES	0	0
STOCKHOLDERS' EQUITY:
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none	0	0
Common stock, $0.10 par value - Authorized-80,000 shares; Issued and outstanding, 20,210 shares at December 31, 2017 and 16,338 shares at December 31, 2016	2,021,000	1,633,000
Additional paid-in capital	625,568,000	162,828,000
Treasury Stock, Value	0	(14,000)
Retained earnings	585,624,000	516,980,000
Accumulated other comprehensive loss	(14,959,000)	(21,272,000)
Total stockholders' equity	1,198,254,000	660,155,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,496,951,000	704,688,000
Allowance for doubtful accounts	$ 3,311,312	$ 1,073,000
Convertible preferred stock, par value	$ 1	$ 1
Convertible preferred stock, authorized shares	500,000	500,000
Convertible preferred stock, issued shares	$ 0	$ 0
Convertible preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.1	$ 0.1
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	20,210,054	16,337,763
Common stock, shares outstanding	20,210,054	16,337,670
Treasury Stock, Common, Shares	0	93

Consolidated Statements of Income - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
REVENUES:
Net sales	$ 1,292,166,000	$ 379,339,000	$ 341,254,000
Other	447,000	33,000	414,000
TOTAL REVENUE	1,292,613,000	379,372,000	341,668,000
COST OF GOODS SOLD	866,518,000	177,974,000	160,871,000
Gross profit	426,095,000	201,398,000	180,797,000
OPERATING EXPENSES:
Selling, general and administrative	303,953,000	89,426,000	83,216,000
Research and development	51,253,000	12,955,000	15,714,000
Restructuring, strategic transaction and integration expenses	77,967,000	15,348,000	8,451,000
Change in fair value of contingent earn-out	8,000,000	0	0
Gain on sale of building	0	0	(1,086,000)
Legal settlements, net	0	0	1,798,000
Impairment of assets held for sale	0	728,000	4,139,000
Total operating expenses	441,173,000	118,457,000	112,232,000
(Loss) Income from operations	(15,078,000)	82,941,000	68,565,000
Bargain Purchase Gain	70,890,000	1,456,000	0
Interest Expense	(2,047,000)	(118,000)	(39,000)
OTHER (EXPENSE) INCOME,NET	(2,482,000)	885,000	1,173,000
Income before income taxes	51,283,000	85,164,000	69,699,000
BENEFIT (PROVISION) FOR INCOME TAXES	17,361,000	(22,080,000)	(24,714,000)
Net Income	$ 68,644,000	$ 63,084,000	$ 44,985,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Basic	$ 3.50	$ 3.90	$ 2.84
Diluted	$ 3.29	$ 3.66	$ 2.73
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	19,614	16,168	15,848
Diluted (in shares)	20,858	17,254	16,496

Statement of Comprehensive Income - USD ($)	12 Months Ended
Statement of Comprehensive Income - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net income	$ 68,644,000	$ 63,084,000	$ 44,985,000
Cash flow hedge adjustments, net of taxes of $224 for the year ended December 31, 2017	(365,000)	0	0
Foreign currency translation adjustment, net of taxes of $56, $185 and ($2,680) for the years ended December 31, 2017, 2016 and 2015, respectively	6,694,000	(514,000)	(11,204,000)
Other adjustments, net of taxes of $0 for the year ended December 31, 2017	(16,000)	0	0
Other Comprehensive Income (Loss), Net of Tax	6,313,000	(514,000)	(11,204,000)
Comprehensive income	74,957,000	62,570,000	33,781,000
Other Comprehensive Income (Loss), Cash Flow Hedge Adjustments, Tax	(224)	0	0
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	56,000	185,000	(2,680,000)
Other Comprehensive (Income) Loss, Other Adjustments, Tax	$ 0	$ 0	$ 0

Consolidated Statements of Stockholders Equity - USD ($) $ in Thousands	Total	Common Stock Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, Shares at Dec. 31, 2014		15,595,000
Balance at Dec. 31, 2014	$ 508,252		$ 1,559	$ 107,336	$ 0	$ 408,911	$ (9,554)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock and exercise of stock options, shares issued		475,000
Treasury Stock, Shares		(18,000)
Employee stock purchase plan, shares issued		34,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	24,372		46	22,715	1,611
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(1,523)			88	(1,611)
Issuance of common stock for acquisitions	0
Proceeds from employee stock purchase plan	2,162		3	2,159	0
Stock compensation	12,827			12,827
Foreign Currency Translation Adjustment	(11,204)						(11,204)
Net Income	44,985					44,985
Balance at Dec. 31, 2015	579,871		1,608	145,125	0	453,896	(20,758)
Balance, Shares at Dec. 31, 2015		16,086,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock and exercise of stock options, shares issued		416,000
Treasury Stock, Shares		(195,000)
Employee stock purchase plan, shares issued		31,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	17,346		22	103	17,221
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(17,235)			0	(17,235)
Issuance of common stock for acquisitions	0
Proceeds from employee stock purchase plan	2,361		3	2,358	0
Stock compensation	15,242			15,242
Foreign Currency Translation Adjustment	(514)						(514)
Net Income	63,084					63,084
Balance at Dec. 31, 2016	$ 660,155		1,633	162,828	(14)	516,980	(21,272)
Balance, Shares at Dec. 31, 2016	16,337,670	16,338,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of restricted stock and exercise of stock options, shares issued		676,000
Treasury Stock, Shares		(27,000)
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,200,000
Employee stock purchase plan, shares issued		23,000
Issuance of restricted stock and exercise of stock options, including excess income tax benefits	$ 32,003		66	27,866	4,071
Purchase of treasury stock,treasury stock acquired in lieu of cash payment on stock option exercises and income tax withholding obligations	(4,057)			0	(4,057)
Issuance of common stock for acquisitions	413,139		320	412,819
Proceeds from employee stock purchase plan	2,705		2	2,703	0
Stock compensation	19,352			19,352
Foreign Currency Translation Adjustment	6,313						6,313
Net Income	68,644					68,644
Balance at Dec. 31, 2017	$ 1,198,254		$ 2,021	$ 625,568	$ 0	$ 585,624	$ (14,959)
Balance, Shares at Dec. 31, 2017	20,210,054	20,210,000

Consolidated Statements of Cash Flows $ in Thousands	12 Months Ended
Consolidated Statements of Cash Flows $ in Thousands	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income	$ 68,644	$ 63,084	$ 44,985
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	66,569	19,050	18,073
Provision for doubtful accounts	2,308	0	54
Provision for warranty and returns	845	559	52
Stock compensation	19,352	15,242	12,827
Loss (gain) on disposal of property and equipment	3,778	59	(1,106)
Bond premium amortization	103	1,355	1,670
Debt issuance cost amortization	48	0	0
Impairment of assets held for sale	0	728	4,139
Bargain Purchase Gain	(70,890)	(1,456)	0
Change in fair value of contingent earn-out	8,000	0	0
Other	(220)	75	0
Changes in operating assets and liabilities
Accounts receivable	(54,533)	744	(20,515)
Inventories	181,699	(5,501)	(8,337)
Prepaid expenses and other assets	(31,807)	(3,028)	(1,832)
Increase (Decrease) in Due from Related Parties, Current	(95,309)	0	0
Accounts payable	46,648	(463)	3,118
Accrued liabilities	33,813	(1,221)	9,454
Income taxes, including excess tax benefits and deferred income taxes	(24,625)	714	1,613
Net cash provided by operating activities	154,423	89,941	64,195
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(74,479)	(23,361)	(12,984)
Proceeds from sale of assets	2	0	3,592
Proceeds from the disposal of assets held for sale	0	3,268	0
Intangible asset additions	(5,203)	(1,192)	(951)
Business acquisitions, net of cash acquired	(162,448)	(2,584)	(56,786)
Proceeds from sale of assets acquired in a business acquisition	0	0	28,970
Purchases of investment securities	(24,743)	(118,384)	(56,137)
Proceeds from sale of investment securities	0	158,534	83,054
Net cash (used in) provided by investing activities	(266,871)	16,281	(11,242)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of Long-term obligations	(75,000)	0	0
Proceeds from exercise of stock options	32,003	17,346	15,042
Proceeds from employee stock purchase plan	2,705	2,361	2,162
Purchase of treasury stock	(4,057)	(17,235)	(1,523)
Net cash (used in) provided by financing activities	(44,349)	2,472	15,681
Effect of exchange rate changes on cash	1,787	224	(8,282)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(155,010)	108,918	60,352
CASH AND CASH EQUIVALENTS, beginning of period	445,082	336,164	275,812
CASH AND CASH EQUIVALENTS, end of period	290,072	445,082	336,164
SUPPLEMENTAL DISCLSOURE OF CASH FLOW INFORMATION
Cash paid during the year for income taxes	5,109	21,101	22,998
Cash paid during the year for interest	2,047	118	39
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES
Accounts payable for property and equipment	5,376	1,566	182
Fair value of assets acquired	886,569	3,306	60,693
Cash paid for acquisitions, net of cash acquired	(162,448)	(2,584)	(56,786)
Proceeds from Issuance of Debt	(75,000)	0	0
Estimated working capital adjustment	4,253	0	0
Contingent consideration	(19,000)	0	0
Issuance of common stock for acquisitions	(413,139)	0	0
Bargain Purchase Gain	(70,890)	(1,456)	0
Goodwill, Acquired During Period	6,536	0	0
Liabilities Assumed/Adjustments to liabilities assumed	(156,881)		$ (3,907)
Adjustments to assumed liabilities		$ (734)
Hospira [Member]
Adjustments to reconcile net income to net cash provided by operating activities:
Bargain Purchase Gain	(70,890)
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES
Proceeds from Issuance of Debt	(75,000)
Contingent consideration	(19,000)
Issuance of common stock for acquisitions	(413,139)
Bargain Purchase Gain	$ (70,890)

General and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

Basis of Presentation and Preparation

ICU Medical, Inc. ("ICU"), a Delaware corporation, operates in one business segment engaged in the development, manufacturing and sale of innovative medical devices used in vascular therapy, and critical care applications. ICU's product portfolio includes intravenous smart pumps, sets, connectors, closed transfer devices for hazardous drugs, cardiac monitoring systems, along with pain management and safety software technology. We sell the majority of our products through our direct sales force and through independent distributors throughout the U. S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. The manufacturing for all product groups occurs in Salt Lake City, Utah, Austin, Texas, Mexico and Costa Rica.

All subsidiaries are wholly owned and are included in the consolidated financial statements. All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.

In our opinion, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash, Cash Equivalents

Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase as cash equivalents.

Accounts Receivable

Accounts receivable are stated at net realizable value. An allowance is provided for estimated collection losses based on an assessment of various factors. We consider prior payment trends, the age of the accounts receivable balances, financial status and other factors to estimate the cash which ultimately will be received. Such amounts cannot be known with certainty at the financial statement date. We regularly review individual past due balances for collectability.

Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Inventory costs include material, labor and overhead related to the manufacturing of medical devices.

Inventories consist of the following at December 31 (in thousands):



	2017		2016
Raw material	$	82,397	$	28,435
Work in process	42,304		4,415
Finished goods	163,956		16,414
Total	$	288,657	$	49,264

Property, Plant and Equipment

Property, plant and equipment consist of the following at December 31 (in thousands):



	2017			2016
Machinery and equipment	$	220,999		$	96,536
Land, building and building improvements	206,846			63,524
Molds	56,253			39,014
Computer equipment and software	44,408			26,458
Furniture and fixtures	7,361			3,243
Instruments placed with customers*	15,812			—
Construction in progress	57,144			15,180
Total property, plant and equipment, cost	608,823			243,955
Accumulated depreciation	(210,139		)	(158,259		)
Net property, plant and equipment	$	398,684		$	85,696

______________________________

*Instruments placed with customers consist of drug-delivery and monitoring systems placed with customer under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 years
Machinery and equipment	2 - 10 years
Furniture, fixtures and molds	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers*	3 - 7 years

We capitalize expenditures that materially increase the life of the related assets; maintenance and repairs are expensed as incurred. The costs and related accumulated depreciation applicable to property, plant and equipment sold or retired are removed from the accounts and any gain or loss is reflected in the statements of income at the time of disposal. Depreciation expense was $51.6 million, $16.3 million and $15.9 million in the years ended December 31, 2017, 2016 and 2015, respectively.

Goodwill

We test goodwill for impairment on an annual basis in the month of November. If the carrying amount of goodwill exceeds the implied estimated fair value, an impairment charge to current operations is recorded to reduce the carrying value to the implied estimated fair value. There were no accumulated impairment losses as of December 31, 2017 and 2016.

The following table presents the changes in the carrying amount of our goodwill for 2017 and 2016 (in thousands):



	Total
Balance as of December 31, 2015	$	6,463
Other⁽¹⁾	(886		)
Balance as of December 31, 2016	5,577
Goodwill acquired⁽²⁾	6,536
Other ⁽³⁾	244
Balance as of December 31, 2017	$	12,357

______________________________

⁽¹⁾In 2016, "other" relates to measurement period adjustments on the net assets of our 2015 acquisition of EXC Holding Corp. ("EXC").

⁽²⁾ In 2017, our Fannin (UK) Limited ("Fannin") acquisition resulted in $1.0 million of goodwill and our Medical Australia Limited ("MLA") acquisition resulted in $5.5 million of goodwill. The goodwill related to MLA is preliminary and subject to adjustment.

⁽³⁾In 2017, "other" relates to foreign currency translation.

Intangible Assets

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average Amortization Life in Years	December 31, 2017
	Weighted Average Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	17,064	$	10,970	$	6,094
Customer contracts	9	5,319		4,892		427
Non-contractual customer relationships	9	55,080		6,562		48,518
Trademarks	4	425		425		—
Trade name	15	7,310		1,096		6,214
Developed technology	11	81,846		7,571		74,275
Total amortized intangible assets		$	167,044	$	31,516	$	135,528

IPR&D		$	8,225			$	8,225

Total intangible assets		$	175,269	$	31,516	$	143,753



	Weighted Average	December 31, 2016
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	14,423	$	9,326	$	5,097
MCDA contract *	10	8,571		8,571		—
Customer contracts	9	5,319		4,512		807
Non-contractual customer relationships	15	7,080		590		6,490
Trademarks	4	425		425		—
Trade name	15	7,310		609		6,701
Developed technology	10	3,797		509		3,288
Total		$	46,925	$	24,542	$	22,383

______________________________

*MCDA contract: Manufacturing, Commercialization and Development Agreement with Hospira, Inc., dated May 1, 2005 (the "MCDA”). The MCDA was terminated in connection with the acquisition of the HIS business on February 3, 2017.

Amortization expense in 2017, 2016 and 2015 was $15.0 million, $2.8 million and $2.2 million, respectively.

As of December 31, 2017 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



2018	$	15,996
2019	15,582
2020	15,444
2021	15,361
2022	15,242
Thereafter	57,903
Total	$	135,528

Long-Lived Assets

We periodically evaluate the recoverability of long-lived assets whenever events and changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When indicators of impairment are present, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of the underlying asset is adjusted to fair value if the sum of the expected discounted cash flows is less than book value. Fair values are based on estimates of market prices and assumptions concerning the amount and timing of estimated future cash flows and discount rates, reflecting varying degrees of perceived risk.

Investment Securities

Short-term investments, exclusive of cash equivalents, are marketable securities intended to be sold within one year and may include trading securities, available-for-sale securities, and held-to-maturity securities (if maturing within one year). Long-term investments are marketable securities intended to be sold after one year and may include trading securities, available-for-sale securities, and held-to-maturity securities.

Our investment securities are considered available-for-sale and are “investment grade” and carried at fair value. Our investments currently consist of corporate bonds. Available-for-sale securities are recorded at fair value, and unrealized holding gains and losses are recorded, net of tax, as a component of accumulated other comprehensive income (loss). Unrealized losses on available-for-sale securities are charged against net earnings when a decline in fair value is determined to be other than temporary. Our management reviews several factors to determine whether a loss is other than temporary, such as the length and extent of the fair value decline, the financial condition and near term prospects of the issuer, and for equity investments, our intent and ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. For debt securities, management also evaluates whether we have the intent to sell or will likely be required to sell before its anticipated recovery. Realized gains and losses are accounted for on the specific identification method. There have been no realized gains or losses on their disposal. The scheduled maturities of the equity securities are between 2018 and 2020. All short-term investment securities are all callable within one year.

As of December 31, 2017, our investment securities consist of the following (in thousands):



	December 31, 2017
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	10,061	$	—	$	10,061
Long-term corporate bonds	14,579		—		14,579
Total investment securities	$	24,640	$	—	$	24,640

Income Taxes

Deferred taxes are determined based on the differences between the financial statements and the tax bases using rates as enacted in the laws. A valuation allowance is established if it is “more likely than not” that all or a portion of the deferred tax assets will not be realized.

We recognize interest and penalties related to unrecognized tax benefits in the tax provision. We recognize liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. We have not recorded any material interest or penalties during any of the years presented.

Foreign Currency

Generally, the functional currency of our international subsidiaries is the local currency. Generally, we translate the financial statements of these subsidiaries to U.S. dollars at the exchange rate in effect at the balance sheet date and revenues and expenses are translated at the average monthly exchange rates during the year. Certain of our international subsidiaries consolidate first with another subsidiary that utilizes a functional currency other than U.S. dollars. In those cases, we follow a step by step translation process utilizing the same sequence as the consolidation process. Translation adjustments are recorded as a component of accumulated other comprehensive income, a separate component of stockholders' equity on our consolidated balance sheets and the effect of exchange rate changes on cash and cash equivalents are reflected on our consolidated statements of cash flows. Gains and losses for transactions denominated in a currency other than the functional currency of the entity are included in our statements of operations in other (expense) income, net. Foreign currency transaction losses, net were $1.8 million in 2017, $0.3 million in 2016 and less than $0.2 million in 2015.

Revenue Recognition

Most of our product sales are free on board shipping point and ownership of the product transfers to the customer on shipment. We record sales and related costs when ownership of the product transfers to the customer, persuasive evidence of an arrangement exists, collectability is reasonably assured and the sales price is determinable. Our customers are distributors, medical product manufacturers and end-users. Our only post-sale obligations are warranty and certain rebates. We warrant products against defects and have a policy permitting the return of defective products. We reserve for warranty and returns based on historical experience. We accrue rebates based on agreements and on historical experience as a reduction in revenue at the time of sale.

Other revenue consists of license, royalty and revenue sharing payments. Payments expected to be received are estimated and recorded in the period earned and adjusted to actual amounts when reports are received from payers; if there is insufficient data to make such estimates, payments are not recorded until reported by the payers.

Arrangements with Multiple Deliverables

In certain circumstances, we enter into arrangements in which we provide multiple deliverables to our customers. These bundled arrangements may include infusion pumps, Mednet software, implementation services, extended warranty and consumables. We first separate the deliverables into different units of accounting and then allocate the arrangement consideration to those separate units of accounting based on their relative selling price. When applying the relative selling price method, the selling price for each deliverable shall be determined using the following hierarchy: (i) vendor-specific objective evidence of selling price; (ii) third-part evidence of selling price; or (iii) best estimate of the selling price. We record revenue related to these multiple deliverables as products are delivered and services have been performed.

Shipping Costs

Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.

Advertising Expenses

Advertising expenses are expensed as incurred and reflected in selling, general and administrative expenses in our consolidated statements of operations and were $0.2 million in 2017, $0.1 million in 2016 and $0.2 million in 2015.

Post-retirement and Post-employment Benefits

We sponsor a Section 401(k) retirement plan ("plan") for employees. Our contributions to our 401(k) plan were approximately $2.0 million in 2017, $1.5 million in 2016 and $1.3 million in 2015. As a result of the HIS acquisition, we assumed certain post-retirement and post-employment obligations related to employees located in certain international countries. These obligations are immaterial to our financial statements taken as a whole.

Research and Development

Research and development costs are expensed as incurred. Research and development costs include salaries and related benefits, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs.

Net Income Per Share

Net income per share is computed by dividing net income by the weighted average number of common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average number of common shares outstanding plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options that are anti-dilutive, where their exercise price exceeds the average market price of the common stock are not included in the treasury stock method calculation. There were 337 anti-dilutive shares in 2017. There were no anti-dilutive shares in 2016 or 2015.

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands except per share data):



	Year ended December 31, (in thousands, except per share data)
	2017		2016		2015
Net income	$	68,644	$	63,084	$	44,985
Weighted average number of common shares outstanding (basic)	19,614		16,168		15,848
Dilutive securities ⁽¹⁾	1,244		1,086		648
Weighted average common and common equivalent shares outstanding (diluted)	20,858		17,254		16,496
EPS - basic	$	3.50	$	3.90	$	2.84
EPS - diluted	$	3.29	$	3.66	$	2.73

______________________________

⁽¹⁾ During the second quarter of 2016, we early adopted ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. Under this ASU, the change to the treasury stock method impacted weighted average common and common equivalent shares outstanding by 413,000 shares for the year ended December 31, 2016.

On February 3, 2017, as part of the purchase price for the acquisition of Pfizer Inc.'s ("Pfizer") Hospira Infusion Systems ("HIS") business, we delivered to Pfizer 3.2 million newly issued common shares (see Note 2: Acquisitions, Strategic Transaction and Integration Expenses).

New Accounting Pronouncements

Recently Adopted Accounting Standards

In July 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2015-11 Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 changes the measurement of inventory within the scope of the ASU (e.g. FIFO or average cost) from lower of cost or market to lower of cost and net realizable value ("NRV"). NRV is defined as estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Prior to the ASU, U.S. generally accepted accounting principles required an entity to measure inventory at the lower of cost or market. Market is measured using replacement cost unless it is above NRV (commonly referred to as “ceiling”) or below NRV less an approximately normal profit margin (commonly referred to as “floor”). For inventory within its scope, the ASU eliminates the notions of replacement cost and NRV less a normal profit margin, which is intended to simplify the accounting for inventory. The amendments are effective prospectively for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2016. We adopted this ASU on January 1, 2017. This ASU did not have a material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In August, 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The amendments in this update change both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results to facilitate financial reporting that more closely reflects an entity's risk management activities. The amendments in this update also make certain targeted improvements to simplify the application of hedge accounting guidance and ease the administrative burden of hedge documentation requirements and assessing hedge effectiveness. The amendments are effective for the fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2018. For cash flow and net investment hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate measurement of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained earnings as of the beginning of the fiscal year that an entity adopts the update. We early-adopted this ASU on January 1, 2018. The adoption of this ASU will not materially impact our first quarter 2018 consolidated financial statements or related footnotes.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Under the ASU, an entity will account for the effects of a modification unless (i) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (ii) the vesting conditions of the modified award are the same vesting conditions as the original award immediately before the original award is modified, and (iii) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The amendments in this ASU are effective prospectively for annual periods, and interim periods within those annual periods, beginning December 15, 2017. This adoption of this ASU is not expected to have a material impact on our consolidated financial statements or related footnote disclosures.

In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. The amendments in this update remove the second step of the impairment test. An entity will apply a one-step quantitative test and record the amount of goodwill impairment as the excess of a reporting unit's carrying amount over its fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The new guidance does not amend the optional qualitative assessment of goodwill impairment. The amendments in ASU 2017-04 are effective for the annual or interim impairment test in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. This ASU is not expected to have a material impact on our consolidated financial statements or related footnote disclosures.

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The amendments in this update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this update provide a screen to determine when a set (integrated set of assets and activities) is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. The amendments in ASU 2017-01 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. The amendments in this ASU should be applied prospectively on or after the effective date. This adoption of this ASU is not expected to have a material impact on our consolidated financial statements or related disclosures.

In October 2016, the FASB issued No. ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory. Current generally accepted accounting principles prohibits the recognition of current and deferred income taxes for an intra-entity asset transfer until after the asset has been sold to an outside party. The amendments in ASU 2016-16 eliminates this prohibition. Accordingly, an entity should recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. Amendments in this update are effective for annual reporting periods beginning after December 15, 2017. The adoption of this ASU is not expected to have a material impact on our consolidated financial statements or related disclosures.

In August 2016, the FASB issued No. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides specific guidance on eight cash flow issues where current guidance is unclear or does not include any specifics on classification. The eight specific cash flow issues are: debt prepayment or debt extinguishment costs; settlement of zero-coupon debt instruments or other debt instruments with zero coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; contingent consideration payments made after a business combination; proceeds from the settlement of insurance claims; proceeds from the settlement of corporate-owned life insurance policies, including bank-owned policies; distributions received from equity method investees; beneficial interests in securitization transactions; and separately identifiable cash flows and application of the predominance principle. The amendments in ASU 2016-15 are effective for annual periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. If adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Amendments should be applied using a retrospective transition method to each period presented. The adoption of this ASU is not expected to have a material impact on the consolidated financial statements and related disclosures.

In June 2016, the FASB issued No. ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This update amends the FASB's guidance on the impairment of financial instruments by requiring timelier recording of credit losses on loans and other financial instruments. The ASU adds an impairment model that is based on expected losses rather than incurred losses. The ASU also amends the accounting for credit losses on available-

for-sale debt securities and purchased financial assets with credit deterioration. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted as of the fiscal years beginning after December

15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.

In February 2016, the FASB issued No. ASU 2016-02, Leases (Topic 842). The amendments in this update require an entity to recognize a right-of-use asset and lease liability for all leases with terms of more than 12 months. Recognition, measurement and presentation of expenses will depend on classification as finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. The amendments in this update will be effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.

In January 2016, the FASB issued No. ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, which amends certain aspects of recognition, measurement, presentation and disclosure of financial instruments. This amendment requires all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in the consolidation of the investee). The amendments in this update will be effective for fiscal years beginning after December 15, 2017. Early adoption of the amendments is not permitted with the exception of the provision requiring the recognition in other comprehensive income the fair value change from instrument-specific credit risk measured using the fair value option for financial instruments. The adoption of this ASU is not expected to have a material impact on the consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 removes inconsistencies and weaknesses in revenue requirements; provides a more robust framework for addressing revenue issues; improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets; provides more useful information to users of financial statements through improved disclosure requirements; and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU 2014-09. On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09. Subsequent to the issuance of this ASU, the FASB issued three amendments: ASU No. 2016-08 which clarifies principal versus agent considerations; ASU 2016-10 which clarifies guidance related to identifying performance obligations and licensing implementation; and ASU 2016-12 which provides narrow-scope improvements and practical expedients. All of the amendments have the same effective dates mentioned above.

We adopted the standard effective January 1, 2018 using the modified retrospective method applied to those contracts that were not completed as of January 1, 2018. Results for reporting beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and will continue to be reported in accordance with our historic accounting under ASC 605. Due to the cumulative impact of adopting ASC 606, we will record a net increase of $9.0 million to opening retained earnings as of January 1, 2018. The impact is primarily related to our bundled arrangements where we sell software licenses and implementation services, in addition to equipment and other consumables and solutions.

We evaluated the effect ASU 2014-09 on our consolidated financial statements by reviewing each of the significant revenue streams. The following is the result of that evaluation:

•

Bundled arrangements - The timing of revenue recognition changed under ASC 606 for arrangements that include the sale of equipment, software and related software implementation services, for which revenue is recognized over time, as the related implementation services are delivered. This results in a delay in the recognition of related revenue over the implementation period, and an acceleration of software related revenue when compared to ASC 605.


•	Software renewals - The timing of revenue recognition for software license renewals changed under ASC 606. As functional IP, the license is transferred to the customer at a point in time, at the start of each annual renewal period. As a result, under ASC 606, revenue related to our annual software license renewals is accelerated compared to ASC 605.

In addition to the impact as mentioned above, we expect to have enhanced disclosures in our 2018 first quarter report on Form 10-Q.

Acquisitions and Strategic Transaction Expenses (Notes)

12 Months Ended

Dec. 31, 2017

Acquisitions and Strategic Transaction Expenses [Abstract]

Acquisitions and Strategic Transaction Expenses [Text Block]

ACQUISITIONS, STRATEGIC TRANSACTION AND INTEGRATION EXPENSES

2017 Acquisitions

On February 1, 2017, we acquired 100% interest in Fannin for total consideration of approximately $1.5 million. Fannin provides infusion therapy consumable products to the healthcare sector in the United Kingdom and Ireland.

On February 3, 2017, we acquired 100% interest in Pfizer's HIS business for total cash consideration of approximately $260.0 million (net of estimated working capital adjustments paid at closing), which was financed with existing cash balances and a $75 million three-year interest-only seller note. We also issued 3.2 million shares of our common stock. The fair value of the common shares issued to Pfizer was determined based on the closing price of our common shares on the closing date, discounted to reflect a contractual lock-up period whereby Pfizer cannot transfer the shares, subject to certain exceptions, until the earlier of (i) the expiration of Pfizer’s services to us in the related transitional services agreement or (ii) eighteen months from the closing date. Additionally, Pfizer also may be entitled up to an additional $225 million in cash contingent consideration based on the achievement of performance targets for the combined company for the three years ending December 31, 2019 ("Earnout Period"). In the event that the sum of our Adjusted EBITDA as defined in the Amended and Restated Stock and Asset Purchase Agreement between us and Pfizer (the “HIS Purchase Agreement”) for the three years in the Earnout Period (the "Cumulative Adjusted EBITDA") is equal to or exceeds approximately $1 billion ("the "Earnout Target"), then Pfizer will be entitled to receive the full amount of the earnout. In the event that the Cumulative Adjusted EBITDA is equal to or greater than 85% of the Earnout Target (but less than the Earnout Target), Pfizer will be entitled to receive the corresponding percentage of the earnout. In the event that the Cumulative Adjusted EBITDA is less than 85% of the Earnout Target, then no earnout amount will be earned by Pfizer. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. We believe that the acquisition of the HIS business, which includes IV pumps, solutions and consumable devices complements our pre-existing business by creating a company that has a complete infusion therapy product portfolio. We believe that the acquisition significantly enhances our global footprint and platform for continued competitiveness and growth.

With the acquisition of HIS, pre-existing long-term supply and distribution contracts between ICU and HIS were effectively terminated.

Deferred Closings

In the HIS Purchase Agreement, we agreed with Pfizer to defer the local closing of the HIS business in certain foreign jurisdictions (the “Deferred Closing Businesses”) for periods ranging by jurisdiction from 3 to 12 months after the February 3, 2017 closing date (the "Deferred Closing Period"). The net assets in these jurisdictions represent an immaterial portion of the total HIS business net assets.

At the February 3, 2017 HIS business transaction closing, we entered into a Net Economic Benefit Agreement with Pfizer under which we agreed that (i) during the Deferred Closing Period, the economic benefits and burdens of the Deferred Closing Businesses are for our account, and we are to be treated as the beneficial owner of the Deferred Closing Businesses and (ii) Pfizer would continue to operate the Deferred Closing Businesses under our direction.

As of December 31, 2017, all of the deferred closing businesses were effectively closed.

Purchase Price

The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):



Cash consideration for acquired assets	$	180,785
Fair value of Seller Note	75,000
Fair value of contingent consideration payable to Pfizer (long-term)	19,000

Issuance of ICU Medical, Inc. common shares:
Number of shares issued to Pfizer	3,200
Price per share (ICU's trading closing share price on the Closing Date)	$	140.75
Market price of ICU shares issued to Pfizer	$	450,400
Less: Discount due to lack of marketability of 8.3%	(37,261		)
Equity portion of purchase price	413,139
Total Consideration	$	687,924

Purchase Price Allocation:
Cash and cash equivalents	$	31,082
Trade receivables	362
Inventories	417,622
Prepaid expenses and other assets	13,911
Property, plant and equipment	288,134
Intangible assets⁽¹⁾	131,000
Other assets	29,270
Accounts payable	(12,381		)
Accrued liabilities	(47,936		)
Long-term liabilities⁽²⁾	(67,170		)
Total identifiable net assets acquired	$	783,894
Deferred tax, net	(25,080		)
Estimated Gain on Bargain Purchase	(70,890		)
Estimated Purchase Consideration	$	687,924

______________________________

⁽¹⁾ Identifiable intangible assets includes $48 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D is non-amortizing until the associated research and development efforts are complete.

⁽²⁾Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.

The fair value of the assets acquired and liabilities assumed exceeded the fair value of the consideration to be paid resulting in a bargain purchase gain. Before recognizing a gain on a bargain purchase, we reassessed the methods used in the purchase accounting and verified that we had identified all of the assets acquired and all of the liabilities assumed, and that there were no additional assets or liabilities to be considered. We also reevaluated the fair value of the contingent consideration transferred to determine that it was appropriate. We determined that the bargain purchase gain was primarily attributable to expected restructuring costs as well as a reduction to the initially agreed upon transaction price caused primarily by revenue shortfalls across all market segments of the HIS business, negative manufacturing variance due to the drop in revenue and higher operating and required stand up costs, when compared to forecasts of the HIS business at the time that the purchase price was agreed upon. After the continuing review of the product demand and operations of the HIS Business, including the resulting expected restructuring activities, we forecasted our estimated Adjusted EBITDA from the HIS business in 2017 to be $35 million - $40 million, which was considerably lower than the forecast contemplated in initial negotiations with Pfizer, which resulted in an estimated fair value of $19 million related to the $225 million earn out. Restructuring costs, if incurred, will be expensed in future periods (see Note 3: Restructuring Charges). The bargain purchase gain is separately stated below income from operations in the accompanying consolidated statements of operations for the year ended December 31, 2017.

The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair market value. The estimated fair value of identifiable intangible assets were developed using the income approach and are based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and estimated useful lives. Fixed assets were valued with the consideration of remaining economic lives. The raw materials inventory was valued at historical cost and adjusted for any obsolescence, the work in process was valued at estimated sales proceeds less costs to complete and costs to sell, and finished goods inventory was valued at estimated sales proceeds less a nominal profit and costs to sell. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.

The pro forma financial information in the table below summarizes the combined results of operations for ICU and HIS as though the companies were combined as of the beginning of fiscal 2016. The pro forma financial information for all periods presented also includes the business combination accounting effects resulting from this acquisition including our amortization charges from acquired intangible assets, nonrecurring expense related to the fair value adjustment to acquisition-date inventory, acquisition and integration-related costs, interest expense on the Pfizer seller note and the related tax effects as though the aforementioned companies were combined as of the beginning of fiscal 2016. The pro forma financial information as presented below is for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisitions had taken place at the beginning of fiscal 2016.



(In millions)	Revenue		Earnings
Actual from 2/3/2017 - 12/31/2017⁽³⁾	$	1,062	*
2017 supplemental pro forma from 1/1/2017 - 12/31/2017⁽¹⁾⁽²⁾	$	1,293	$	180
2016 supplemental pro forma from 1/1/2016 - 12/31/2016⁽¹⁾⁽²⁾	$	1,418	$	22

______________________________

* Impracticable to calculate.

⁽¹⁾2017 supplemental pro forma earnings were adjusted to exclude $66.3 million of nonrecurring expense related to the fair value adjustment to acquisition-date inventory and $69.5 million of acquisition and integration-related costs. 2016 supplemental pro forma earnings were adjusted to include these charges.

⁽²⁾Unaudited.

⁽³⁾ Amount represents activity of HIS from the date of the acquisition.

On November 29, 2017, we acquired all of the outstanding shares of MLA. Total cash consideration paid was approximately $9.0 million. MLA delivers similar consumable Infusion products as our current businesses to Australia and surrounding regions. The purchase price allocation is preliminary and subject to future revision as the acquired assets and liabilities assumed are dependent upon the finalization of the related valuations.

2016 Acquisitions

On April 4, 2016, we acquired all of the outstanding shares of Tangent Medical Technologies, Inc. ("Tangent") for $2.6 million in cash. Tangent designs, develops, and commercializes intravenous catheters and associated products for the improvement of infusion therapy. Tangent's products enhance our infusion therapy product offering. For the year ended December 31, 2016, we recognized a $1.5 million bargain purchase gain related to the acquisition, which is separately stated in our consolidated statements of income. The bargain purchase gain represents the excess of the estimated fair market value of the identifiable tangible and intangible assets acquired, liabilities assumed and deferred tax assets over the total purchase consideration. The bargain purchase was driven by our ability to realize acquired deferred tax assets. The purchase price allocation is final.

2015 Acquisitions

On October 6, 2015, we acquired 100% of the outstanding shares of EXC, for approximately $59.5 million in cash. Immediately following the completion of the acquisition of EXC, we sold certain assets to Excelsior Medical, LLC for a final purchase price including working capital adjustments of $29.0 million in cash. We retained all of the assets related to the business of manufacturing and selling the needleless connector disinfection cap. The acquisition of EXC's SwabCap business enhances our infusion therapy product offering across our existing direct and original equipment manufacturer business lines. The goodwill recognized for this acquisition is attributable to the benefits expected to be derived from product line expansion, new customers and operational synergies. The goodwill is nondeductible for income tax purposes. The following table summarizes the final purchase price and the allocation of the purchase price related to the assets and liabilities retained (in thousands):



Fair Value of Consideration:
Cash, net of cash acquired	$	56,786

Allocation of the Purchase Price:
Net assets sold to Excelsior Medical, LLC	$	28,970
Prepaid expenses and other current assets	254
Deferred tax asset/liabilities	4,426
Property, plant and equipment	3,982
Identifiable intangible assets⁽¹⁾	18,076
Goodwill	4,985
Assumed liabilities	(3,907		)
Net Assets Acquired	$	56,786

______________________________

⁽¹⁾ Identifiable intangible assets included $7.1 million of non-contractual customer relationships, $3.7 million of developed technology and $7.3 million of trade name. The weighted-average amortization period for the total identifiable intangible assets is approximately fourteen years. The weighted-average amortization period for customer relationships and trade name is fifteen years and the weighted-average amortization period for the developed technology is ten years.

The identifiable intangible assets and other long-lived assets acquired have been valued as Level 3 assets at fair market The estimated fair value of identifiable intangible assets was developed using the income approach and is based on critical estimates, judgments and assumptions derived from: analysis of market conditions; discount rate; discounted cash flows; royalty rates; customer retention rates; and estimated useful lives. The prepaid expenses and other current assets and assumed liabilities were recorded at their carrying values as of the date of the acquisition, as their carrying values approximated their fair values due to their short-term nature.

Strategic Transaction and Integration Expenses

In 2017, we incurred $59.2 million in transaction and integration costs primarily related to our acquisition of HIS. In 2016, we incurred $14.3 million in transaction costs related to our 2017 acquisition of HIS, our acquisition of Tangent and our acquisition of EXC. In 2015, we incurred $1.8 million in charges primarily associated with the acquisition of EXC. Transaction expenses are presented on a separate line item on our statements of income and are combined with restructuring charges.

Restructuring Charges (Notes)

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

e incurred restructuring charges related to the acquisition of the HIS business (see Note 2: Acquisitions, Strategic Transaction and Integration Expenses). The restructuring charges were incurred as a result of integrating the acquired operations into our business and include severance costs related to involuntary employee terminations and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer. All material charges in regard to these restructuring activities have been paid as of December 31, 2017.

In 2016, we incurred an additional $0.8 million related to the closure of the Slovakian manufacturing facility, described below. Additionally, we incurred $0.2 million related to a one-time charge unrelated to the events disclosed in the table below.

In 2015, we incurred $6.7 million in total restructuring charges related to: (i) a commitment to a plan to sell our Slovakia manufacturing facility, which was sold during 2016. The plan to sell the facility resulted in a pre-tax restructuring charge of $4.2 million for employee termination benefits, government incentive repayments and other associated costs; (ii) an

agreement with Dr. Lopez, a member of our Board of Directors and a former employee in our research and development department, pursuant to which we bought out Dr. Lopez's right to employment under his then-existing employment agreement-the $1.9 million buy-out, including payroll taxes, will be paid in equal monthly installments until December 2020 and payments that will exceed one year have been accrued under long-term liabilities in our consolidated balance sheet; and (iii) the reorganization of our corporate infrastructure, resulting in one-time employee termination benefits and other associated costs and corporate restructuring actions resulted in a total charge of $0.6 million.

The following table summarizes the activity for the restructuring-related charges discussed above and related accrual (in thousands):



	Accrued Balance December 31, 2015		Charges incurred		Payments			Currency Translation		Other Adjustments			Accrued Balance December 31, 2016		Charges incurred		Payments			Other Adjustments			Accrued Balance December 31, 2017
Severance pay and benefits	$	2,505	$	25	$	(2,683	)	$	77	$	129		$	53	$	15,983	$	(15,104	)	$	(17	)	$	915
Government incentive repayment	1,884		—		(1,769		)	57		(172		)	—		—		—			—			—
Employment agreement buyout	1,845		—		(368		)	—		—			1,477		—		(363		)	—			1,114
Other corporate restructuring	305		168		(468		)	—		(5		)	—		—		—			—			—
Retention and facility closure expenses	—		581		(581		)	—		—			—		2,789		(2,789		)	—			—
	$	6,539	$	774	$	(5,869	)	$	134	$	(48	)	$	1,530	$	18,772	$	(18,256	)	$	(17	)	$	2,029

Gain on Sale of Building (Notes)	12 Months Ended
Gain on Sale of Building (Notes)	Dec. 31, 2017
Gain on Sale of Building [Abstract]
Gain on sale of building [Text Block]	GAIN ON SALE OF BUILDING During 2015, we sold an office building in our San Clemente location to George A. Lopez, M.D., a member of our Board of Directors. The building was sold for $3.6 million, its fair market value as determined by a third party. The net book value of the land and building was $2.5 million resulting in a gain on the sale of the land and building of $1.1 million.

Legal settlements (Notes)	12 Months Ended
Legal settlements (Notes)	Dec. 31, 2017
Legal Settlements [Abstract]
Legal settlement [Text Block]	LEGAL SETTLEMENTS During 2015, we recorded a net settlement charge of $1.8 million due to the following claims: An arbitrator ruled on a breach of contract claim between us and a service provider, awarding us a gross settlement of $8.8 million. Our legal counsel for this matter represented us under a contingency fee agreement. We recorded a settlement award, net of legal fees and costs, of $5.3 million; and An arbitrator ruled on a breach of contract claim between us and a customer, Hospira, Inc., awarding Hospira $8.2 million Canadian dollars ($6.5 million U.S. dollars). The arbitrator also ruled that we pay 75% of Hospira's legal fees and expenses, which were $0.7 million U.S. dollars. We made a $7.5 million U.S. dollars settlement payment during 2015, which includes a foreign exchange transaction adjustment to Canadian dollars at the time of payment.

Impairment on assets held for sale (Notes)	12 Months Ended
Impairment on assets held for sale (Notes)	Dec. 31, 2017
Impairment of assets held for sale [Abstract]
Asset Impairment Charges [Text Block]	IMPAIRMENT OF ASSETS HELD FOR SALE During 2015, our Board of Directors authorized us to close our Vrable, Slovakia manufacturing facility. The closure was to enable for greater efficiency of our Ensenada, Mexico facility. After receiving the Board of Director's authorization, we reclassified the land and building related to the Slovakia facility as held-for-sale, and recorded the value of those assets at the lower of their carrying value or their estimated fair value less costs to sell, which was based on a third party fair market valuation. As the estimated fair value less cost to sell was lower than the carrying value of the assets held-for-sale, we recorded an impairment charge of $4.1 million in 2015. During 2016, we completed the closure of our Slovakia manufacturing facility and sold the land and building held-for- sale for $3.3 million, net of costs to sell, resulting in an additional $0.7 million impairment charge on those assets. The impairment charges are separately stated in our consolidated statements of operations above income from operations.

Share Based Award Share awards (Notes)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

SHARE BASED AWARDS

We have a stock incentive plan for employees and directors and an employee stock purchase plan. Shares to be issued under these plans will be issued either from authorized but unissued shares or from treasury shares.

We incur stock compensation expense for stock options, restricted stock units ("RSU"), performance restricted stock units ("PRSU") and stock purchased under our employee stock purchase plan ("ESPP"). We receive a tax benefit on stock compensation expense and direct tax benefits from the exercise of stock options. We also have indirect tax benefits upon exercise of stock options related to research and development tax credits which are recorded as a reduction of income tax expense. The table below summarizes compensation costs and related tax benefits (in thousands):



	Year ended December 31,
(In thousands)	2017		2016		2015
Stock compensation expense	$	19,352	$	15,242	$	12,827
Tax benefit from stock-based compensation cost	$	7,247	$	5,682	$	4,922
Indirect tax benefit	$	1,374	$	—	$	1,997

As of December 31, 2017, we had $23.3 million of unamortized stock compensation cost which we will recognize as an expense over approximately 0.8 years.

Stock Incentive and Stock Option Plans

Our 2011 Stock Incentive Plan ("2011 Plan") replaced our 2003 Stock Option Plan (“2003 Plan”). Our 2011 Plan initially had 650,000 shares available for issuance, plus the remaining available shares for grant from the 2003 Plan. In 2012, 2014 and 2017, our stockholders approved amendments to the 2011 plan that increased the shares available for issuance by 3,275,000, bringing the initial shares available for issuance to 3,925,000, plus the remaining 248,700 shares that remained available for grant from the 2003 Plan. In addition, any forfeited, terminated or expired shares that would otherwise return to the 2003 Plan are available under the 2011 Plan. As of December 31, 2017, the 2011 Plan has 4,188,300 shares of common stock reserved for issuance to employees, which includes 263,300 shares that transferred from the 2003 Plan. Shares issued as options or stock appreciation rights ("SARs") are charged against the 2011 Plan's share reserve as one share for one share issued. Shares subject to awards other than options and SARs are charged against the 2011 Plan's share reserve as 2.09 shares for 1 share issued. Options may be granted with exercise prices at no less than fair market value at date of grant. Options granted under the 2011 Plan may be “non-statutory stock options” which expire no more than ten years from date of grant or “incentive stock options” as defined in Section 422 of the Internal Revenue Code of 1986, as amended. Upon exercise of non-statutory stock options, we are generally entitled to a tax deduction on the exercise of the option for an amount equal to the excess over the exercise price of the fair market value of the shares at the date of exercise; we are generally not entitled to any tax deduction on the exercise of an incentive stock option. The 2011 Plan includes conditions whereby unvested options are cancelled if employment is terminated.

In 2014, our Compensation Committee of the Board of Directors awarded our then new Chief Executive Officer an employment inducement option to purchase 182,366 shares of our common stock and an employment inducement grant of restricted stock units with respect to 68,039 shares of our common stock. The inducement grants were made out of our 2014 Inducement Incentive Plan ("2014 Plan").

Our 2001 Directors’ Stock Option Plan (the “Directors’ Plan”), initially had 750,000 shares reserved for issuance to members of our Board of Directors, expired in November 2011. Although no new grants may be made under the Director's Plan, grants made under the Director's Plan prior to its expiration continue to remain outstanding. Options not vested terminate if the directorship is terminated.

Time-based Stock Options

To date, all options granted under the 2014 Plan, 2011 Plan, 2003 Plan and Directors' Plan have been non-statutory stock options. The majority of the time-based outstanding employee option grants vest 25% after one year from the grant date and the balance vests ratably on a monthly basis over 36 months. The majority of the outstanding options granted to non-employee directors vest one year from the grant date. The options generally expire 10 years from the grant date.

The fair value of time-based option grants is calculated using the Black-Scholes option valuation model. The expected term for the option grants was based on historical experience and expected future employee behavior. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock, based on the average expected exercise term. The table below summarizes the total time-based stock options granted, total valuation and the weighted average assumptions (dollars in thousands):



	Year ended December 31,
	2017			2016			2015
Number of time-based options granted	8,825			13,405			22,816
Grant date fair value of options granted (in thousands)	$	375		$	413		$	590
Weighted average assumptions for stock option valuation:
Expected term (years)	5.5			5.5			5.6
Expected stock price volatility	27.0		%	31.8		%	25.9		%
Risk-free interest rate	1.1		%	0.7		%	1.7		%
Expected dividend yield	—		%	—		%	—		%
Weighted average grant price per option	$	158.20		$	101.32		$	93.30
Weighted average grant date fair value per option	$	42.51		$	30.78		$	25.86

Performance Stock Options

In 2015, we granted performance stock option grants which are exercisable if the common stock price condition and the time-based vesting have been met. The 2015 performance based stock option grants vest ratably at 33% per year over three years. For the 2015 grants, the vested performance stock options became exercisable when the closing price of our common stock was equal to or more than 130% of the exercise price for 30 consecutive trading days during the term of the grant. All of the 2015 performance stock option grant's common stock price conditions have been met.

The fair value of performance option grants is calculated using the Monte Carlo Simulation. The expected term of the performance option grants is based on the expected number of years to achieve the exercisable goal trigger and assumes that the vested option will be immediately exercised or cancelled, if underwater. We estimate the volatility of our common stock at the date of grant based on the historical volatility of our common stock over a 10-year period.

The table below summarizes the performance stock options granted, the total valuation and the weighted average assumptions (dollars in thousands). There were no performance option grants in 2017 or 2016.



	Year ended December 31,
	2017	2016	2015
Number of performance options granted			244,825
Number of performance options earned		244,825	349,812
Grant date fair value of options granted (in thousands)			$	6,087
Weighted average assumptions for stock option valuation:
Expected term (years)			3.0
Expected stock price volatility			30.86		%
Risk-free interest rate			2.3		%
Expected dividend yield			—		%
Weighted average grant price per option			$	91.88
Weighted average grant date fair value per option			$	24.86

A summary of our stock option activity as of and for the year ended December 31, 2017 is as follows:



	Shares		Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2016	2,018,290		$	58.90
Granted	8,825		$	158.20
Exercised	(610,316	)	$	52.43
Forfeited or expired	(72	)	$	58.79
Outstanding at December 31, 2017	1,416,727		$	62.30	5.8	$	217,749
Exercisable at December 31, 2017	1,133,734		$	60.13	5.6	$	176,721
Vested and expected to vest, December 31, 2017	1,416,727		$	62.30	5.8	$	217,749

The intrinsic values for options exercisable, outstanding and vested or expected to vest at December 31, 2017 is based on our closing stock price of $216.00 at December 31, 2017 and are before applicable taxes.



	Year ended December 31,
(In thousands)	2017		2016		2015
Intrinsic value of options exercised	$	71,283	$	25,065	$	28,071
Cash received from exercise of stock options	$	32,003	$	17,346	$	15,042
Tax benefit from stock option exercises	$	20,004	$	7,556	$	9,330

Stock Awards

In 2017, we granted performance restricted stock units ("PRSU") to our executive officers. The PRSUs will vest, if at all, upon the achievement of a minimum Cumulative Adjusted EBITDA, subject to a three-year cliff vesting ending on December 31, 2019. If at that date, our Cumulative Adjusted EBITDA is at least $600 million but less than $650 million, 100% of the awarded units will vest. If our Cumulative Adjusted EBITDA is at least $650 million but less than $700 million, 200% of the awarded units will vest. If our Cumulative Adjusted EBITDA is at least $700 million, 300% of the awarded units will vest.

In 2016, we granted PRSUs to our executive officers, which will vest, if at all, upon the achievement of a minimum specified compound annual growth rate ("CAGR") in adjusted EBITDA per share, subject to a three-year cliff vesting ending on December 31, 2018. If at that date, our adjusted EBITDA per share CAGR is at least 8% but less than 10%, 100% of the awarded units will vest. If our adjusted EBITDA per share CAGR is at least 10% but less than 12%, 200% of the awarded units will vest. If our adjusted EBITDA per share CAGR is greater than 12%, 300% of the awarded units will vest. As of October 1, 2017 we expect our adjusted EBITDA per share CAGR to be greater than 12% at December 31, 2018.

Restricted stock units ("RSU") are granted annually to our Board of Directors and vest on the first anniversary of the grant date.

In 2017, 2016 and 2015, we granted RSUs to certain employees that vest ratably on the anniversary of the grant over three years. Additionally in 2015, we granted RSUs to certain new hire employees that vest ratably on the anniversary of the grant over two years.

The table below summarizes our restricted stock award activity (dollars in thousands):



	Year ended December 31,
(In thousands except shares and per share amounts)	2017		2016		2015
PRSU
Shares granted	20,686		36,370		—
Shares earned	—		—		—
Grant date fair value per share	$	154.75	$	86.47	$	—
Grant date fair value	$	3,201	$	3,145	$	—
Intrinsic value vested	$	—	$	—	$	787

RSU
Shares granted	107,678		60,377		67,745
Grant date fair value per share	$	156.49	$	87.47	$	93.52
Grant date fair value	$	16,851	$	5,281	$	6,336
Intrinsic value vested	$	9,813	$	4,680	$	2,754

The table below provides a summary of our PRSU and RSU activity as of and for the year ended December 31, 2017.



	Number of Units		Grant Date Fair Value Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
Non-vested at December 31, 2016	159,439		$	84.68
Change in units due to performance expectations^(a)	72,740		$	86.47
Granted	128,364		$	156.21
Vested	(66,278	)	$	80.61
Forfeited	(8,762	)	$	148.76
Non-vested and expected to vest at December 31, 2017	285,503		$	116.28	1.0	$	33,197

(a) Relates to the 2016 PRSUs, assumes attainment of maximum payout rate as set forth in performance criteria.

ESPP

We have an ESPP under which U.S. employees may purchase up to $25,000 annually of common stock at 85% of its fair market value at the beginning or the end of a six-month offering period, whichever is lower. There are 750,000 shares of common stock reserved for issuance under the ESPP, which is subject to an annual increase of the least of 300,000 shares, two percent of the shares outstanding or such a number as determined by the Board. To date, there have been no increases. As of December 31, 2017, there were 133,487 shares available for future issuance. The ESPP is intended to constitute an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. During 2017, we suspended our ESPP.

The fair value of rights to purchase shares under the ESPP is calculated using the Black-Scholes option valuation model. The table below summarizes the number and intrinsic value of ESPP share purchases and the weighted average valuation assumptions for the 2017, 2016 and 2015 purchase periods.



	Year ended December 31,
	2017			2016			2015
ESPP shares purchased by employees	23,426			31,227			34,299
Intrinsic value of ESPP purchases (in thousands)	$	986		$	955		$	1,382
Weighted average assumptions for ESPP valuation:
Expected term (in years)	0.5			0.5			0.5
Expected stock price volatility	28.1		%	32.5		%	27.0		%
Risk-free interest rate	0.6		%	0.3		%	0.6		%
Expected dividend yield	—		%	—		%	—		%

Derivatives and Hedging Activities (Notes)

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

DERIVATIVES AND HEDGING ACTIVITIES

Hedge Accounting and Hedging Program

During the second quarter of 2017, we implemented a cash flow hedging program. The purpose of our hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.

In May 2017, we entered into a two-year cross-currency par forward contract to hedge a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instrument is recorded at fair value on the Consolidated Balance Sheets and is classified based on the instrument's maturity date. We record changes in the intrinsic value of the effective portion of the gain or loss on the derivative instrument as a component of Other Comprehensive (Loss) Income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Any gain or loss on the derivative instrument due to ineffectiveness of the hedge will be recognized in the Consolidated Statements of Operations during the current period. The total notional amount of our outstanding derivative as of December 31, 2017 was approximately 510.3 million MXN. The term of our currency forward contract is May 1, 2017 to May 1, 2019. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 20.01MXN/USD over the term of the two-year contract.

The following table presents the fair values of our derivative instrument included within the Consolidated Balance Sheet as of December 31, 2017 (in thousands):



	Derivatives
	Consolidated Balance Sheet Location	December 31, 2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Accrued liabilities	$	187
	Other long-term liabilities	402
Total derivatives designated as cash flow hedging instruments		$	589

The following table presents the amounts affecting the Consolidated Statements of Operations for the year ended December 31, 2017 (in thousands):



	Line Item in the Consolidated Statements of Operations	Year Ended December 31, 2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	885

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives		Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Year Ended December 31, 2017		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	Year Ended December 31, 2017
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	296	Cost of goods sold	$	885
Total derivatives designated as cash flow hedging instruments	$	296		$	885

As of December 31, 2017, we expect approximately $0.2 million of the deferred losses on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next 12 months concurrent with the underlying hedged transactions also being reported in net income.

Fair Value Measurements (Notes)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

FAIR VALUE MEASUREMENTS

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:


•	Level 1: quoted prices in active markets for identical assets or liabilities;

•

Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or


•	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

During the first quarter of 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer may be entitled up to $225 million in cash if certain performance targets for the combined company for the three years ending December 31, 2019 are achieved. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The initial value assigned to the contingent consideration was a result of forecasted product demand of our HIS business, as discussed further in Note 2: Acquisition, Strategic Transaction and Integration Expenses. At each reporting date subsequent to the acquisition we remeasure the earn-out using the same methodology above and recognize any changes in value. If the probability of achieving the performance target significantly changes from what we initially anticipated, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our consolidated balance sheets.

The following table provides a reconciliation of the Level 3 earn-out liability measured at estimated fair value based on an initial valuation and updated quarterly for the year ended December 31, 2017 (in thousands):



	Earn-out Liability
Contingent earn-out liability, December 31, 2016	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	8,000
Contingent earn-out liability, December 31, 2017	$	27,000

The fair value of the earn-out at December 31, 2017 changed from the fair value calculated at acquisition due to a change in the forecast of the underlying target, adjusted EBITDA, and due to changes in other assumptions used in the Monte Carlo simulation, as detailed in the below table.

The following table provides quantitative information about Level 3 inputs for fair value measurement of our earn-out liability as of the acquisition date and December 31, 2017. Significant increases or decreases in these inputs in isolation could result in a significant impact on our fair value measurement:



Simulation Input	As of December 31, 2017		At Acquisition February 3, 2017
Adjusted EBITDA Volatility	26.00	%	29.00	%
WACC	8.75	%	10.00	%
20-year risk free rate	2.58	%	2.82	%
Market price of risk	5.99	%	6.93	%
Cost of debt	4.08	%	4.16	%

The fair value of our investments, which consisted of corporate bonds, is estimated using observable market based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs.

The fair value of our Level 2 forward currency contract is estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

The assets related to our Dominican Republic manufacturing facilities are classified as assets held-for-sale. These assets are separately stated in our consolidated balance sheet. The fair value of these Level 3 assets was determined as part of the HIS business valuation and was based on a market approach using comparable building and land sales data and the analysis of market conditions.

There were no transfers between levels in 2017.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at December 31, 2017
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	10,061	$	—	$	10,061	$	—
Long-term	14,579		—		14,579		—
Total Assets	$	24,640	$	—	$	24,640	$	—

Liabilities:

Earn-out liability	$	27,000	$	—	$	—	$	27,000
Foreign exchange forwards:
Accrued liabilities	187		—		187		—
Other long-term liabilities	402		—		402		—
Total Liabilities	$	27,589	$	—	$	589	$	27,000

Our assets measured at fair value on a nonrecurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above (in thousands):



	Fair value measurements at December 31, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Assets held-for-sale	$	12,489	$	—	$	—	$	12,489
Total Assets	$	12,489	$	—	$	—	$	12,489

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Prepaids and Other Current Assets (Notes)

12 Months Ended

Dec. 31, 2017

Prepaid Expense and Other Assets, Current [Abstract]

Other Current Assets [Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):



	2017		2016
Deposits	$	21,940	$	—
Other prepaid expenses and receivables	4,208		2,948
Prepaid insurance and property taxes	2,580		1,649
VAT/GST receivable	8,097		1,018
Deferred tax charge	1,326		—
Other	3,135		1,740
	$	41,286	$	7,355

Related-party receivables consist of the following (in thousands):



	2017		2016
Third-party receivables due from Pfizer	$	36,425	$	—
HIS business acquisition related	62,382		—
	$	98,807	$	—

Third-party receivables due from Pfizer relates to trade accounts receivable that has already been collected from customers by Pfizer on our behalf.

Accrued Liabilities an Other Long-term Liabilities

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

ACCRUED LIABILITIES AND OTHER LONG-TERM LIABILITIES

Accrued liabilities consist of the following (in thousands):



	December 31,
	2017		2016
Salaries and benefits	$	20,745	$	5,702
Incentive compensation	40,682		7,912
Accrued professional fees	13,319		—
Accrued product field action	11,810		—
Consigned inventory	5,210		—
Third-party inventory	4,284		—
Legal accrual	3,538		4,177
Accrued sales taxes	6,291		1,472
Warranties and Returns	3,360		—
Deferred revenue	3,326		18
Accrued other taxes	2,771		—
Outside commissions	725		1,141
Accrued freight	5,696		—
Restructuring accrual	1,290		423
Acquisition-related accrual	—		2,750
Other	9,017		2,301
	$	132,064	$	25,896

Other long-term liabilities consist of the following (in thousands):



	December 31,
	2017		2016
Contract liabilities⁽¹⁾	$	40,148	$	—
Deferred revenue	7,099		—
Benefits	2,104		1,107
Other	5,975		—
	$	55,326	$	1,107

__________________________________________

⁽¹⁾ Consists of multiple contracts with customers and suppliers that were valued at below market at the time of the HIS acquisition.

Long-Term Obligations (Notes)

12 Months Ended

Dec. 31, 2017

LOng-Term Obligations Disclosure [Abstract]

Debt Disclosure [Text Block]

LONG-TERM OBLIGATIONS

Five-year Revolving Credit Facility ("Credit Facility")

On November 8, 2017, we entered into a five-year Revolving Credit Facility ("Credit Facility") with various lenders for $150 million, with Wells Fargo Bank, N.A. as the administrative agent, swingline lender and issuing lender. As of December 31, 2017, we had no borrowings and $150 million of availability under the Credit Facility. The Credit Facility matures on November 8, 2022.

The Credit Facility has an accordion feature that would enable us to increase the borrowing capacity of the Credit Facility by the greater of (i) $100 million and (ii) 2.00x Total Leverage.

In connection with the Credit Facility, for the year ended December 31, 2017, we incurred $1.4 million in financing costs, which were capitalized and are included in prepaid expenses and other current assets and other assets in our consolidated balance sheets, in accordance with the appropriate short-term or long-term classification. These fees will be amortized to interest expense over the remaining term of the Credit Facility.

Principal payments

Principal payments, when drawn on the Credit Facility, are made at our discretion with the entire unpaid amount due at maturity.

Interest rate

In general, borrowing under the Credit Facility (other than Swingline loans) bears interest, at our option, based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") rate plus applicable margin, as defined below:

(A) Base Rate is defined as the highest of: (a) the Prime Rate; (b) the Federal Funds Rate plus 0.50%; and (c) the daily LIBOR (as defined below) for a one month Interest Period plus 1%.

(B) LIBOR Rate, as determined by the Administrative Agent, is defined as the rate per annum obtained by dividing (1) LIBOR by (2) 1.00 - Eurodollar Reserve Percentage.

Swingline loans will bear interest at the Base Rate plus the applicable Interest Margin. The Credit Facility has a per annum commitment fee (see table below) that will accrue on the unused amounts of the commitments under the Credit Facility.

The applicable interest margins and the commitment fee with respect to the Credit Facility shall be based on the Total Leverage Ratio pursuant to the following pricing grid:



Level	Consolidated Total Leverage Ratio	Commitment Fee	LIBOR +	Base Rate +
I	Less than 1.00 to 1.00	0.15%	1.25%	0.25%
II	Greater than or equal to 1.00 to 1.00 but less than 2.00 to 1.00	0.20%	1.50%	0.50%
III	Greater than or equal to 2.00 to 1.00 but less than 2.50 to 1.00	0.25%	1.75%	0.75%
IV	Greater than or equal to 2.50 to 1.00	0.30%	2.00%	1.00%

Guarantors and Collateral

Our obligations under the Credit Facility are unconditionally guaranteed, on a joint and several basis, by ICU Medical, Inc. and certain of our existing subsidiaries. Our obligations are secured by: (i) 100% of the equity interests of our guarantor subsidiaries; and (ii) all of the tangible and intangible personal property and assets related to us and our guarantor subsidiaries (including, without limitation, all accounts, equipment, inventory and other goods, all instruments, intellectual property and other general intangibles, deposit accounts, securities accounts and other investment property and cash), and (iii) all products, profits and proceeds of the foregoing. Notwithstanding the foregoing, the collateral shall not include certain excluded property.

Debt Covenants

The Credit Facility contains certain financial covenants pertaining to Consolidated Fixed Charge Coverage and Consolidated Total Leverage Ratios. In addition, the Credit Facility has restrictions pertaining to limitations on debt, liens, negative pledges, loans, advances, acquisitions, other investments, dividends, distributions, redemptions, repurchases of equity interests, fundamental changes and asset sales and other dispositions, prepayments, redemptions and purchases of subordinated debt and other junior debt, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business, fiscal year and accounting practices and amendment of organizational documents and junior debt documents.

The Consolidated Leverage Ratio is defined as the ratio of Consolidated Total Funded Indebtedness on such date, to Consolidated Adjusted EBITDA, as defined under the Credit Facility Agreement, for the most recently completed four fiscal quarters. The maximum Consolidated Leverage Ratio is not more than 3.00 to 1.00.

The Consolidated Fixed Charge Coverage Ratio is defined as the ratio of: (a) Consolidated Adjusted EBITDA less the sum of (i) capital expenditures, (ii) federal, state, local and foreign income taxes paid in cash and (iii) cash restricted payments made after the closing date, to (b) Consolidated Fixed Charges for the most recently completed four fiscal quarters, calculated on a pro forma basis. The minimum Consolidated Fixed Charge Coverage Ratio is 2.00 to 1.00.

We were in compliance with all financial covenants as of December 31, 2017.

Three-Year Interest-Only Senior Note

On February 3, 2017, we partially funded the acquisition of the HIS business from Pfizer with a $75 million Seller Note issued by Pfizer contemporaneous with the acquisition. We had fully repaid the seller note as of December 31, 2017.

Income Taxes:

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

Income from continuing operations before taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016		2015
United States	$	59,872		$	80,714	$	74,288
Foreign	(8,589		)	4,450		(4,589		)
	$	51,283		$	85,164	$	69,699

The (benefit) provision for income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016			2015
Current:
Federal	$	2,774		$	21,123		$	18,601
State	2,263			2,347			745
Foreign	3,170			1,118			1,426
	8,207			24,588			20,772
Deferred:
Federal	$	(20,878	)	$	(2,045	)	$	4,524
State	(4,619		)	(767		)	(960		)
Foreign	(71		)	304			378
	(25,568		)	(2,508		)	3,942
	$	(17,361	)	$	22,080		$	24,714

Current income taxes payable were reduced from the amounts in the above table by $9.3 million in 2015, equal to the direct tax benefit that we receive upon exercise of stock options and the vesting of restricted stock units by employees and directors. We have accrued for tax contingencies for potential tax assessments, and in 2017 we recognized a $3.0 million net increase, most of which related to various federal and state tax reserves.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted into legislation, which includes a broad range of provisions affecting businesses. The Tax Act significantly revises how companies compute their U.S. corporate tax liability by, among other provisions, reducing the corporate tax rate from 35% to 21% for tax years beginning after December 31, 2017, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the toll charge or transition tax.

Pursuant to the SEC Staff Accounting Bulletin ("SAB") No. 118, "Income Tax Accounting Implications of the Tax Cuts and Jobs Act" ("SAB 118"), a company selects between one of three scenarios to reflect the impact of the Tax Act in its financial statements within a measurement period. Those scenarios are (i) a final estimate which effectively closes the measurement period; (ii) a reasonable estimate leaving the measurement period open for future revisions; and (iii) no estimate as the law is still being analyzed in which case a company continues to apply its accounting on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. SAB 118 allows for the reporting provisional amounts for certain income tax effects in scenario (ii) and (iii). The measurement period begins in the reporting period that includes the Act’s enactment date and ends when an entity has obtained, prepared, and analyzed the information that was needed in order to complete the accounting requirements under ASC Topic 740. We were able to provide a reasonable estimate for the revaluation of deferred taxes and the effects of the toll charge on undistributed foreign earnings and profits, with our measurement period open for future revisions. As such, we recorded a provisional tax expense in the amount of $1.1 million and a provisional tax expense in the amount of $2.0 million related to the revaluation of deferred taxes and the toll charge, respectively. We are still evaluating various international provisions included in the Tax Act and have therefore not completed our assessment. These provisions include, but are not limited to, the anti-base-erosion and anti-abuse tax regime (BEAT), the global intangible low-taxed income (GILTI) provisions, the foreign derived intangible income (FDII) provisions, and the changes to the deductibility of interest. These provisions will be effective for us beginning on January 1, 2018, and may materially impact our effective tax rate in future years.

A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):



	Year Ended December 31,
	2017					2016					2015
	Amount			Percent		Amount			Percent		Amount			Percent
Federal tax at the expected statutory rate	$	17,950		35.0	%	$	29,807		35.0	%	$	24,395		35.0	%
State income tax, net of federal effect	(403		)	(0.8	)%	1,795			2.1	%	2,661			3.9	%
Tax credits	(2,783		)	(5.4	)%	(1,014		)	(1.2	)%	(5,861		)	(8.4	)%
Foreign income tax differential	3,481			6.8	%	(135		)	(0.1	)%	3,412			4.9	%
Stock based compensation	(18,958		)	(37.0	)%	(7,720		)	(9.1	)%	—			—	%
Impact of the Tax Act	3,076			6.0	%	—			—	%	—			—	%
IP installment sale	3,367			6.6	%	—			—	%	—			—	%
Bargain purchase gain	(24,811		)	(48.4	)%	—			—	%	—			—	%
Other	1,720			3.4	%	(653		)	(0.8	)%	107			0.1	%
	$	(17,361	)	(33.8	)%	$	22,080		25.9	%	$	24,714		35.5	%

Tax credits in 2017, 2016 and 2015 consist principally of research and developmental tax credits.

The components of our deferred income tax assets (liabilities) are as follows (in thousands):



	December 31,
	2017			2016
Deferred tax asset:
Foreign	$	—		$	1,223
Accruals/other	8,368			857
Acquired future tax deductions	10,580			6,473
Stock-based compensation	8,633			11,089
Foreign currency translation adjustments	3,425			5,175
Tax credits state	8,471			6,764
Foreign tax credits	2,749			—
Inventory reserves	10,658			1,938
Allowance for doubtful accounts	636			151
Valuation allowance	(7,385		)	—
	$	46,135		$	33,670
Deferred tax liability:
State income taxes	$	1,640		$	1,708
Foreign	202			1,370
Depreciation and amortization	21,005			10,027
	$	22,847		$	13,105

Deferred tax asset, net	$	23,288		$	20,565

Tax Holidays and Carryforwards

Acquired future tax deductions consist of: (a) the net tax benefit of items expensed for financial statement purposes but capitalized and amortized for tax purposes, (b) the total tax benefited portion of the federal net operating loss ("NOL") carry-forwards of $4.9 million which will expire at various dates from 2020 to 2035 and (c) the net tax benefited portion of the foreign NOLs of $1.1 million, consisting of a NOL of $6.6 million with a valuation allowance of $5.5 million. Under Section 382 of the Internal Revenue Code, certain ownership changes limit the utilization of the NOL carry-forwards, and the amount of federal NOL carry-forwards recorded is the net federal benefit available.

Other carryforwards include research and development (“R&D”) state tax credit carryforwards of $9.5 million and $0.3 million for California and Utah, respectively, and a foreign tax credit carryforward of $2.7 million.

A substantial portion of our manufacturing operations in Costa Rica operate under various tax holidays and tax incentive programs which will expire in whole or in part in 2027. Certain of the holidays and may be extended if specific conditions are met. The net impact of these tax holidays and tax incentives was an increase to our net earnings by $5.7 million or $0.27 per diluted share in 2017.

Foreign currency translation adjustments, and related tax effects, are an element of “other comprehensive income” and are not included in net income other than the revaluation of the associated deferred tax asset due to the Tax Act.

As of December 31, 2017, we had estimated $24 million of undistributed foreign earnings and profits. Pursuant to the Tax Act, our undistributed foreign earnings and profits were deemed repatriated as of December 31, 2017. We have not provided deferred tax liabilities for foreign withholding taxes and certain state income taxes on the undistributed earnings and profits from certain non-U.S. subsidiaries that will be permanently reinvested outside the United States.

Upon the distribution of foreign earnings and profits, certain foreign countries impose withholding taxes, subject to certain limitations, for use as credits against our U.S. tax liability, if any. If the foreign earnings and profits were distributed, we would need to accrue an additional income tax liability. However, we may also be allowed a credit against substantially all our U.S. tax liability for the taxes paid in foreign jurisdictions.

We are subject to taxation in the United States and various states and foreign jurisdictions. Our United States federal income tax returns for tax years 2014 and forward are subject to examination by the Internal Revenue Service. Our principal state income tax returns for tax years 2012 and forward are subject to examination by the state tax authorities. The total gross amount of unrecognized tax benefits as of December 31, 2017 was $6.5 million which, if recognized, would impact the effective tax rate. We believe that adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax examinations cannot be predicted with certainty. As of December 31, 2017, it is not possible to estimate the amount of change, if any, in the unrecognized tax benefits that is reasonably possible within the next twelve months. We recognize accrued interest and penalties related to unrecognized tax benefits as a component of income tax expense. We have not accrued any penalties or interest as of December 31, 2017 or December 31, 2016

The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):



	Year Ended December 31,
	2017			2016			2015
Beginning balance	$	2,000		$	1,772		$	4,115
Increases to prior year tax positions	77			77			25
Increases due to acquisitions	640			—			—
Increases to current year tax positions	3,992			345			345
Decreases to prior year tax positions	(12		)	(46		)	(2,399		)
Decrease related to settlements	—			—			(314		)
Decrease related to lapse of statute of limitations	(170		)	(148		)	—
Ending balance	$	6,527		$	2,000		$	1,772

Market Segments, Geographic Information and Significant Customers Market Segments, Geographic Information and Significant Customers (Notes)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Information by Geographic Area and Customer Concentration [Text Block]

PRODUCT LINES, GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS

Our primary product lines are Infusion Consumables, IV Solutions, Infusion Systems and Critical Care. The following table sets forth for the periods indicated, total revenue by product line as a percentage of total revenue:



	Year Ended December 31,
Product line	2017		2016		2015
Infusion Consumables	28	%	86	%	84	%
IV Solutions	40	%	—	%	—	%
Infusion Systems	23	%	—	%	—	%
Critical Care	4	%	14	%	16	%
Other	5	%	—	%	—	%
	100	%	100	%	100	%

We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2016 and 2015, we had worldwide sales to one manufacturer, Pfizer, of 30% and 36%, respectively, of consolidated revenue and as of December 31, 2016, accounts receivable from Pfizer was 23% of consolidated accounts receivable.

In February 2017, we completed the acquisition of Pfizer's HIS business, which we acquired in part to protect against the significant earnings exposure indicated above (see Note 2: Acquisitions and Strategic Transaction Expenses).

We report revenue on a “where-sold” basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer.

The table below presents total company revenues, by major country or region (in thousands):



	As of December 31,
	2017		2016		2015
Europe	$	100,423	$	50,105	$	45,062
Canada	69,753		16,266		12,494
LATAM	57,851		29,920		27,780
APAC	54,465		10,304		7,047
Other	30,184		11,083		10,622
Total foreign	$	312,676	$	117,678	$	103,005
United States	979,937		261,694		238,663
Worldwide total	$	1,292,613	$	379,372	$	341,668

Domestic sales accounted for 76%, 70% and 71% of total revenue in 2017, 2016 and 2015, respectively. International sales accounted for 24%, 30% and 29% of total revenue in 2017, 2016 and 2015, respectively.

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):



	As of December 31,
	2017		2016
Costa Rica	$	80,956	$	—
Mexico	61,008		57,971
Other LATAM	19,432		—
Canada	4,362		—
Italy	6,860		4,320
Spain	5,601		—
Other Europe	2,625		966
APAC	5,169		41
Total foreign	$	186,013	$	63,298
United States	422,810		180,657
Worldwide total	$	608,823	$	243,955

Stockholders' Equity

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Attributable to Parent [Abstract]

Treasury Stock [Text Block]

Stockholders' Equity

Treasury Stock

In July 2010, our Board of Directors approved a common stock purchase plan to purchase up to $40.0 million of our common stock. This plan has no expiration date and we have $7.2 million remaining on this purchase plan. During 2016, we purchased $15.4 million of our common stock. We did not purchase any of our common stock under our purchase plan in 2017 or 2015. We used the treasury stock to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Facility, (see Note 12: Long-Term Obligations).

In 2017, we withheld 27,636 shares of our common stock from employee vested restricted stock units in consideration for $4.1 million in payments for the employee's share award income tax withholding obligations. We have no shares remaining in treasury at December 31, 2017.

In 2016, we withheld 20,261 shares of our common stock from employee vested restricted stock units in consideration for $1.9 million in payments for the employee's share award income tax withholding obligations. We had 93 shares remaining in treasury at December 31, 2016.

Accumulated Other Comprehensive Income (Loss)

The components of AOCI, net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of December 31, 2016	$	(21,272	)	$	—		$	—		$	(21,272	)
Other comprehensive income (loss) before reclassifications	6,694			184			(16		)	6,862
Amounts reclassified from AOCI	—			(549		)	—			(549		)
Other comprehensive income (loss)	6,694			(365		)	(16		)	6,313
Balance as of December 31, 2017	$	(14,578	)	$	(365	)	$	(16	)	$	(14,959	)

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Lease Commitments

We have entered into various non-cancellable operating lease agreements for certain of our offices and facilities throughout the world with original lease periods expiring primarily between 2018 and 2024. Some of these agreements have escalating rent payment provisions. We recognize rent expense under such agreements on a straight-line basis.

Our rent expense under operating leases was $7.9 million in 2017, $0.6 million in 2016 and $0.4 million in 2015.

As of December 31, 2017, future minimum lease payments under our non-cancelable operating leases are as follows over each of the next five years and thereafter (in millions):



2018	$	8,775
2019	5,907
2020	4,059
2021	3,214
2022	3,105
Thereafter	6,446
Total	$	31,506

Legal Proceedings

Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Pfizer subsidiaries, Hospira, Inc., Hospira Worldwide, Inc. and certain other defendants relating to the intravenous saline solutions part of the HIS business. Plaintiffs seek to represent classes consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants’ allegedly unlawful conduct ceases. Plaintiffs allege that the defendants’ conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. On February 3, 2017, we completed the acquisition of the HIS business from Pfizer. This litigation is the subject of a claim for indemnification against us by Pfizer and a cross-claim for indemnification against Pfizer by us under the HIS stock and asset purchase agreement ("SAPA").

In addition, in August 2015, the New York Attorney General issued a subpoena to Hospira, Inc. requesting that the company provide information regarding certain business practices in the intravenous solutions part of the HIS business. Separately, in April 2017, we received a grand jury subpoena issued by the United States District Court for the Eastern District of Pennsylvania, in connection with an investigation by the U.S. Department of Justice, Antitrust Division. The subpoena calls for production of documents related to the manufacturing, selling, pricing and shortages of intravenous solutions, including saline, as well as communications among market participants regarding these issues. The Department of Justice investigation is the subject of cross-claims for indemnification by both us and Pfizer under the SAPA. We will coordinate with Pfizer to produce records to the New York Attorney General and the Department of Justice.

We have an ongoing dispute with a product partner that may result in a redefinition of our contractual arrangement or in the rights or remedies determined under such arrangement. We do not expect this dispute to have a material adverse effect on our financial position or results of operations.

In addition to the legal matters described above, we are from time to time involved in various legal proceedings, either as a defendant or plaintiff, most of which are routine litigation in the normal course of business. We believe that the resolution of the legal proceedings in which we are involved will not have a material adverse effect on our financial position or results of operations.

Off Balance Sheet Arrangements

In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. We have never incurred, nor do we expect to incur, any liability for indemnification.

Contingencies

We have a contractual earn-out arrangement in connection with our acquisition of the HIS business, whereby Pfizer may be entitled up to an additional $225 million in cash upon achievement of performance targets for the company for the three years ending December 31, 2019, see (Note 2: Acquisitions and Strategic Transaction Expenses). The amount to be paid cannot be determined until the earn-out period has expired.

Commitments and Contingencies Leases (Notes)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Leases of Lessee Disclosure [Text Block]

Lease Commitments

Our rent expense under operating leases was $7.9 million in 2017, $0.6 million in 2016 and $0.4 million in 2015.

As of December 31, 2017, future minimum lease payments under our non-cancelable operating leases are as follows over each of the next five years and thereafter (in millions):



2018	$	8,775
2019	5,907
2020	4,059
2021	3,214
2022	3,105
Thereafter	6,446
Total	$	31,506

Collaborative and Other Arrangements (Notes)	12 Months Ended
Collaborative and Other Arrangements (Notes)	Dec. 31, 2017
Collaborative and Other Arrangements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	COLLABORATIVE AND OTHER ARRANGEMENTS On February 3, 2017, we entered into two MSA's, (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSA's provide each party with mutually beneficial interests and both of the MSA's are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On February 3, 2017, as part of the HIS business acquisition, we entered into an agreement with Pfizer, whereby Pfizer will provide certain transitional services to us for finance, business technology, regulatory, human resources, global operations, procurement, quality and global commercial operation services ("Enabling Function Services"). We pay a monthly service fee for each service provided, and share equally with Pfizer in certain set-up costs and, as applicable, service exit costs. Our share of the set-up costs and service exit costs, in the aggregate, are not to exceed $22.0 million. The service fees are subject to a fee cap of (i) $62.5 million during the initial twelve month period and (ii) $31.3 million during the subsequent six month period. Only the Enabling Function Services are subject to the fee cap, any services provided after expiration of the agreement or services that are not Enabling Function Services may result in service fees outside the fee cap. The service fees are intended to reasonably approximate Pfizer’s cost of providing the Enabling Function Services. We may terminate, in whole only, any particular service and the fee cap would be reduced proportionate to the services terminated. Partial reduction in the provision of any specific service may be made but only with the prior written consent of Pfizer. On February 3, 2017, as part of the HIS business acquisition, we also entered into a reverse transitional services agreement, where we will provide to Pfizer certain transitional services ranging in term from three to eighteen months. Services include support for real estate, research and development, infrastructure, logistics, quality, site operations, safety, commercial and finance, and regulatory support services.

Selected Quarterly Financial Data - Unaudited

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data - Unaudited [Abstract]

Quarterly Financial Information [Text Block]

SELECTED QUARTERLY FINANCIAL DATA - UNAUDITED



	Quarter Ended
	Mar. 31		Jun. 30			Sept. 30		Dec. 31
	(in thousands except per share data)
2017
Total revenue	$	247,739	$	331,514		$	343,236	$	370,124
Gross profit	$	88,945	$	88,062		$	111,598	$	137,490
Net income (loss)	$	55,863	$	(37,060	)	$	136	$	49,705
Net income (loss) per share:
Basic	$	3.03	$	(1.87	)	$	0.01	$	2.47
Diluted	$	2.86	$	(1.87	)	$	0.01	$	2.33
2016
Total revenue	$	89,855	$	96,721		$	97,108	$	95,688
Gross profit	$	49,233	$	50,132		$	51,273	$	50,760
Net income	$	18,160	$	16,606		$	18,806	$	9,512
Net income per share:
Basic	$	1.13	$	1.03		$	1.16	$	0.58
Diluted	$	1.08	$	0.98		$	1.09	$	0.54

______________________________________

On February 3, 2017, we acquired HIS, see Note 2, Acquisitions, Strategic Transaction and Integration Costs.

General and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Business Description and Basis of Presentation [Text Block]

Basis of Presentation and Preparation

Use of Estimates, Policy [Policy Text Block]

Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Inventory, Policy [Policy Text Block]

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.

Property, Plant and Equipment, Policy [Policy Text Block]

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 years
Machinery and equipment	2 - 10 years
Furniture, fixtures and molds	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers*	3 - 7 years

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

Investment, Policy [Policy Text Block]

Investment Securities

Income Tax, Policy [Policy Text Block]

Income Taxes

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Arrangements with Multiple Deliverables

Shipping and Handling Cost, Policy [Policy Text Block]

Shipping Costs

Costs to ship finished goods to our customers are included in cost of goods sold on the consolidated statements of operations.

Advertising Costs, Policy [Policy Text Block]

Advertising Expenses

Pension and Other Postretirement Plans, Policy [Policy Text Block]

Post-retirement and Post-employment Benefits

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Earnings Per Share, Policy [Policy Text Block]

Net Income Per Share

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

15, 2018. The updated guidance requires a modified retrospective adoption. We are currently evaluating the impact of this ASU on the consolidated financial statements and related disclosures.

We evaluated the effect ASU 2014-09 on our consolidated financial statements by reviewing each of the significant revenue streams. The following is the result of that evaluation:

•


•	Software renewals - The timing of revenue recognition for software license renewals changed under ASC 606. As functional IP, the license is transferred to the customer at a point in time, at the start of each annual renewal period. As a result, under ASC 606, revenue related to our annual software license renewals is accelerated compared to ASC 605.

In addition to the impact as mentioned above, we expect to have enhanced disclosures in our 2018 first quarter report on Form 10-Q.

General and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following at December 31 (in thousands):



	2017		2016
Raw material	$	82,397	$	28,435
Work in process	42,304		4,415
Finished goods	163,956		16,414
Total	$	288,657	$	49,264

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment consist of the following at December 31 (in thousands):



	2017			2016
Machinery and equipment	$	220,999		$	96,536
Land, building and building improvements	206,846			63,524
Molds	56,253			39,014
Computer equipment and software	44,408			26,458
Furniture and fixtures	7,361			3,243
Instruments placed with customers*	15,812			—
Construction in progress	57,144			15,180
Total property, plant and equipment, cost	608,823			243,955
Accumulated depreciation	(210,139		)	(158,259		)
Net property, plant and equipment	$	398,684		$	85,696

______________________________

*Instruments placed with customers consist of drug-delivery and monitoring systems placed with customer under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 years
Machinery and equipment	2 - 10 years
Furniture, fixtures and molds	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers*	3 - 7 years

Schedule of Intangible Assets and Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill for 2017 and 2016 (in thousands):



	Total
Balance as of December 31, 2015	$	6,463
Other⁽¹⁾	(886		)
Balance as of December 31, 2016	5,577
Goodwill acquired⁽²⁾	6,536
Other ⁽³⁾	244
Balance as of December 31, 2017	$	12,357

______________________________

⁽¹⁾In 2016, "other" relates to measurement period adjustments on the net assets of our 2015 acquisition of EXC Holding Corp. ("EXC").

⁽³⁾In 2017, "other" relates to foreign currency translation.

Intangible Assets

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average Amortization Life in Years	December 31, 2017
	Weighted Average Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	17,064	$	10,970	$	6,094
Customer contracts	9	5,319		4,892		427
Non-contractual customer relationships	9	55,080		6,562		48,518
Trademarks	4	425		425		—
Trade name	15	7,310		1,096		6,214
Developed technology	11	81,846		7,571		74,275
Total amortized intangible assets		$	167,044	$	31,516	$	135,528

IPR&D		$	8,225			$	8,225

Total intangible assets		$	175,269	$	31,516	$	143,753



	Weighted Average	December 31, 2016
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	14,423	$	9,326	$	5,097
MCDA contract *	10	8,571		8,571		—
Customer contracts	9	5,319		4,512		807
Non-contractual customer relationships	15	7,080		590		6,490
Trademarks	4	425		425		—
Trade name	15	7,310		609		6,701
Developed technology	10	3,797		509		3,288
Total		$	46,925	$	24,542	$	22,383

______________________________

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of December 31, 2017 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



2018	$	15,996
2019	15,582
2020	15,444
2021	15,361
2022	15,242
Thereafter	57,903
Total	$	135,528

Available-for-sale Securities [Table Text Block]

As of December 31, 2017, our investment securities consist of the following (in thousands):



	December 31, 2017
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	10,061	$	—	$	10,061
Long-term corporate bonds	14,579		—		14,579
Total investment securities	$	24,640	$	—	$	24,640

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands except per share data):



	Year ended December 31, (in thousands, except per share data)
	2017		2016		2015
Net income	$	68,644	$	63,084	$	44,985
Weighted average number of common shares outstanding (basic)	19,614		16,168		15,848
Dilutive securities ⁽¹⁾	1,244		1,086		648
Weighted average common and common equivalent shares outstanding (diluted)	20,858		17,254		16,496
EPS - basic	$	3.50	$	3.90	$	2.84
EPS - diluted	$	3.29	$	3.66	$	2.73

______________________________

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Acquisitions and Strategic Transaction Expenses Business Combination (Tables)

12 Months Ended

Dec. 31, 2017

Dec. 31, 2015

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]



(In millions)	Revenue		Earnings
Actual from 2/3/2017 - 12/31/2017⁽³⁾	$	1,062	*
2017 supplemental pro forma from 1/1/2017 - 12/31/2017⁽¹⁾⁽²⁾	$	1,293	$	180
2016 supplemental pro forma from 1/1/2016 - 12/31/2016⁽¹⁾⁽²⁾	$	1,418	$	22

______________________________

* Impracticable to calculate.

Excelsior [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The following table summarizes the final purchase price and the allocation of the purchase price related to the assets and liabilities retained (in thousands):



Fair Value of Consideration:
Cash, net of cash acquired	$	56,786

Allocation of the Purchase Price:
Net assets sold to Excelsior Medical, LLC	$	28,970
Prepaid expenses and other current assets	254
Deferred tax asset/liabilities	4,426
Property, plant and equipment	3,982
Identifiable intangible assets⁽¹⁾	18,076
Goodwill	4,985
Assumed liabilities	(3,907		)
Net Assets Acquired	$	56,786

______________________________

Hospira [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):



Cash consideration for acquired assets	$	180,785
Fair value of Seller Note	75,000
Fair value of contingent consideration payable to Pfizer (long-term)	19,000

Issuance of ICU Medical, Inc. common shares:
Number of shares issued to Pfizer	3,200
Price per share (ICU's trading closing share price on the Closing Date)	$	140.75
Market price of ICU shares issued to Pfizer	$	450,400
Less: Discount due to lack of marketability of 8.3%	(37,261		)
Equity portion of purchase price	413,139
Total Consideration	$	687,924

Purchase Price Allocation:
Cash and cash equivalents	$	31,082
Trade receivables	362
Inventories	417,622
Prepaid expenses and other assets	13,911
Property, plant and equipment	288,134
Intangible assets⁽¹⁾	131,000
Other assets	29,270
Accounts payable	(12,381		)
Accrued liabilities	(47,936		)
Long-term liabilities⁽²⁾	(67,170		)
Total identifiable net assets acquired	$	783,894
Deferred tax, net	(25,080		)
Estimated Gain on Bargain Purchase	(70,890		)
Estimated Purchase Consideration	$	687,924

______________________________

⁽²⁾Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.

Restructuring Charges Schedule of Restructuring and Related Costs (Tables)

12 Months Ended

Dec. 31, 2017

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the activity for the restructuring-related charges discussed above and related accrual (in thousands):



	Accrued Balance December 31, 2015		Charges incurred		Payments			Currency Translation		Other Adjustments			Accrued Balance December 31, 2016		Charges incurred		Payments			Other Adjustments			Accrued Balance December 31, 2017
Severance pay and benefits	$	2,505	$	25	$	(2,683	)	$	77	$	129		$	53	$	15,983	$	(15,104	)	$	(17	)	$	915
Government incentive repayment	1,884		—		(1,769		)	57		(172		)	—		—		—			—			—
Employment agreement buyout	1,845		—		(368		)	—		—			1,477		—		(363		)	—			1,114
Other corporate restructuring	305		168		(468		)	—		(5		)	—		—		—			—			—
Retention and facility closure expenses	—		581		(581		)	—		—			—		2,789		(2,789		)	—			—
	$	6,539	$	774	$	(5,869	)	$	134	$	(48	)	$	1,530	$	18,772	$	(18,256	)	$	(17	)	$	2,029

Share Based Award (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of stock compensation and related tax benefits [Table Text Block]

The table below summarizes compensation costs and related tax benefits (in thousands):



	Year ended December 31,
(In thousands)	2017		2016		2015
Stock compensation expense	$	19,352	$	15,242	$	12,827
Tax benefit from stock-based compensation cost	$	7,247	$	5,682	$	4,922
Indirect tax benefit	$	1,374	$	—	$	1,997

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The table below summarizes the total time-based stock options granted, total valuation and the weighted average assumptions (dollars in thousands):



	Year ended December 31,
	2017			2016			2015
Number of time-based options granted	8,825			13,405			22,816
Grant date fair value of options granted (in thousands)	$	375		$	413		$	590
Weighted average assumptions for stock option valuation:
Expected term (years)	5.5			5.5			5.6
Expected stock price volatility	27.0		%	31.8		%	25.9		%
Risk-free interest rate	1.1		%	0.7		%	1.7		%
Expected dividend yield	—		%	—		%	—		%
Weighted average grant price per option	$	158.20		$	101.32		$	93.30
Weighted average grant date fair value per option	$	42.51		$	30.78		$	25.86

Schedule of Share-based compensation, performance stock option activity [Table Text Block]



	Year ended December 31,
	2017	2016	2015
Number of performance options granted			244,825
Number of performance options earned		244,825	349,812
Grant date fair value of options granted (in thousands)			$	6,087
Weighted average assumptions for stock option valuation:
Expected term (years)			3.0
Expected stock price volatility			30.86		%
Risk-free interest rate			2.3		%
Expected dividend yield			—		%
Weighted average grant price per option			$	91.88
Weighted average grant date fair value per option			$	24.86

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of our stock option activity as of and for the year ended December 31, 2017 is as follows:



	Shares		Weighted Average Exercise Price Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Outstanding at December 31, 2016	2,018,290		$	58.90
Granted	8,825		$	158.20
Exercised	(610,316	)	$	52.43
Forfeited or expired	(72	)	$	58.79
Outstanding at December 31, 2017	1,416,727		$	62.30	5.8	$	217,749
Exercisable at December 31, 2017	1,133,734		$	60.13	5.6	$	176,721
Vested and expected to vest, December 31, 2017	1,416,727		$	62.30	5.8	$	217,749

Exercised Options Data [Table Text Block]



	Year ended December 31,
(In thousands)	2017		2016		2015
Intrinsic value of options exercised	$	71,283	$	25,065	$	28,071
Cash received from exercise of stock options	$	32,003	$	17,346	$	15,042
Tax benefit from stock option exercises	$	20,004	$	7,556	$	9,330

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

The table below summarizes our restricted stock award activity (dollars in thousands):



	Year ended December 31,
(In thousands except shares and per share amounts)	2017		2016		2015
PRSU
Shares granted	20,686		36,370		—
Shares earned	—		—		—
Grant date fair value per share	$	154.75	$	86.47	$	—
Grant date fair value	$	3,201	$	3,145	$	—
Intrinsic value vested	$	—	$	—	$	787

RSU
Shares granted	107,678		60,377		67,745
Grant date fair value per share	$	156.49	$	87.47	$	93.52
Grant date fair value	$	16,851	$	5,281	$	6,336
Intrinsic value vested	$	9,813	$	4,680	$	2,754

Nonvested Restricted Stock Shares Activity [Table Text Block]

The table below provides a summary of our PRSU and RSU activity as of and for the year ended December 31, 2017.



	Number of Units		Grant Date Fair Value Per Share		Weighted Average Contractual Life (Years)	Aggregate Intrinsic Value
Non-vested at December 31, 2016	159,439		$	84.68
Change in units due to performance expectations^(a)	72,740		$	86.47
Granted	128,364		$	156.21
Vested	(66,278	)	$	80.61
Forfeited	(8,762	)	$	148.76
Non-vested and expected to vest at December 31, 2017	285,503		$	116.28	1.0	$	33,197

Schedule of employee stock purchase plan (ESPP) [Table Text Block]

The table below summarizes the number and intrinsic value of ESPP share purchases and the weighted average valuation assumptions for the 2017, 2016 and 2015 purchase periods.



	Year ended December 31,
	2017			2016			2015
ESPP shares purchased by employees	23,426			31,227			34,299
Intrinsic value of ESPP purchases (in thousands)	$	986		$	955		$	1,382
Weighted average assumptions for ESPP valuation:
Expected term (in years)	0.5			0.5			0.5
Expected stock price volatility	28.1		%	32.5		%	27.0		%
Risk-free interest rate	0.6		%	0.3		%	0.6		%
Expected dividend yield	—		%	—		%	—		%

Derivatives and Hedging Activities (Tables)

12 Months Ended

Dec. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table presents the fair values of our derivative instrument included within the Consolidated Balance Sheet as of December 31, 2017 (in thousands):



	Derivatives
	Consolidated Balance Sheet Location	December 31, 2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:	Accrued liabilities	$	187
	Other long-term liabilities	402
Total derivatives designated as cash flow hedging instruments		$	589

The following table presents the amounts affecting the Consolidated Statements of Operations for the year ended December 31, 2017 (in thousands):



	Line Item in the Consolidated Statements of Operations	Year Ended December 31, 2017
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	885

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

We recognized the following gains on our foreign exchange contract designated as a cash flow hedge (in thousands):



	Amount of Gain Recognized in Other Comprehensive Income on Derivatives		Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Year Ended December 31, 2017		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	Year Ended December 31, 2017
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	296	Cost of goods sold	$	885
Total derivatives designated as cash flow hedging instruments	$	296		$	885

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]



	Earn-out Liability
Contingent earn-out liability, December 31, 2016	$	—
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	8,000
Contingent earn-out liability, December 31, 2017	$	27,000

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]



Simulation Input	As of December 31, 2017		At Acquisition February 3, 2017
Adjusted EBITDA Volatility	26.00	%	29.00	%
WACC	8.75	%	10.00	%
20-year risk free rate	2.58	%	2.82	%
Market price of risk	5.99	%	6.93	%
Cost of debt	4.08	%	4.16	%

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):



	Fair value measurements at December 31, 2017
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	10,061	$	—	$	10,061	$	—
Long-term	14,579		—		14,579		—
Total Assets	$	24,640	$	—	$	24,640	$	—

Liabilities:

Earn-out liability	$	27,000	$	—	$	—	$	27,000
Foreign exchange forwards:
Accrued liabilities	187		—		187		—
Other long-term liabilities	402		—		402		—
Total Liabilities	$	27,589	$	—	$	589	$	27,000

Fair Value Measurements, Nonrecurring [Table Text Block]

Our assets measured at fair value on a nonrecurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above (in thousands):



	Fair value measurements at December 31, 2017 using
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Assets held-for-sale	$	12,489	$	—	$	—	$	12,489
Total Assets	$	12,489	$	—	$	—	$	12,489

Prepaids and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2017

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets [Table Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):



	2017		2016
Deposits	$	21,940	$	—
Other prepaid expenses and receivables	4,208		2,948
Prepaid insurance and property taxes	2,580		1,649
VAT/GST receivable	8,097		1,018
Deferred tax charge	1,326		—
Other	3,135		1,740
	$	41,286	$	7,355

Related-party receivables consist of the following (in thousands):



	2017		2016
Third-party receivables due from Pfizer	$	36,425	$	—
HIS business acquisition related	62,382		—
	$	98,807	$	—

Accrued Liabilities an Other Long-term Liabilities (Tables)

12 Months Ended

Dec. 31, 2017

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands):



	December 31,
	2017		2016
Salaries and benefits	$	20,745	$	5,702
Incentive compensation	40,682		7,912
Accrued professional fees	13,319		—
Accrued product field action	11,810		—
Consigned inventory	5,210		—
Third-party inventory	4,284		—
Legal accrual	3,538		4,177
Accrued sales taxes	6,291		1,472
Warranties and Returns	3,360		—
Deferred revenue	3,326		18
Accrued other taxes	2,771		—
Outside commissions	725		1,141
Accrued freight	5,696		—
Restructuring accrual	1,290		423
Acquisition-related accrual	—		2,750
Other	9,017		2,301
	$	132,064	$	25,896

Other long-term liabilities consist of the following (in thousands):



	December 31,
	2017		2016
Contract liabilities⁽¹⁾	$	40,148	$	—
Deferred revenue	7,099		—
Benefits	2,104		1,107
Other	5,975		—
	$	55,326	$	1,107

__________________________________________

⁽¹⁾ Consists of multiple contracts with customers and suppliers that were valued at below market at the time of the HIS acquisition.

Long-Term Obligations (Tables)

12 Months Ended

Dec. 31, 2017

LOng-Term Obligations Disclosure [Abstract]

Interest Margin and Commitment Fee [Table Text Block]

The applicable interest margins and the commitment fee with respect to the Credit Facility shall be based on the Total Leverage Ratio pursuant to the following pricing grid:



Level	Consolidated Total Leverage Ratio	Commitment Fee	LIBOR +	Base Rate +
I	Less than 1.00 to 1.00	0.15%	1.25%	0.25%
II	Greater than or equal to 1.00 to 1.00 but less than 2.00 to 1.00	0.20%	1.50%	0.50%
III	Greater than or equal to 2.00 to 1.00 but less than 2.50 to 1.00	0.25%	1.75%	0.75%
IV	Greater than or equal to 2.50 to 1.00	0.30%	2.00%	1.00%

Income Taxes Income tax disclosure (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

Income from continuing operations before taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016		2015
United States	$	59,872		$	80,714	$	74,288
Foreign	(8,589		)	4,450		(4,589		)
	$	51,283		$	85,164	$	69,699

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The (benefit) provision for income taxes consisted of the following (in thousands):



	Year Ended December 31,
	2017			2016			2015
Current:
Federal	$	2,774		$	21,123		$	18,601
State	2,263			2,347			745
Foreign	3,170			1,118			1,426
	8,207			24,588			20,772
Deferred:
Federal	$	(20,878	)	$	(2,045	)	$	4,524
State	(4,619		)	(767		)	(960		)
Foreign	(71		)	304			378
	(25,568		)	(2,508		)	3,942
	$	(17,361	)	$	22,080		$	24,714

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

A reconciliation of the provision for income taxes at the statutory rate to our effective tax rate is as follows (dollars in thousands):



	Year Ended December 31,
	2017					2016					2015
	Amount			Percent		Amount			Percent		Amount			Percent
Federal tax at the expected statutory rate	$	17,950		35.0	%	$	29,807		35.0	%	$	24,395		35.0	%
State income tax, net of federal effect	(403		)	(0.8	)%	1,795			2.1	%	2,661			3.9	%
Tax credits	(2,783		)	(5.4	)%	(1,014		)	(1.2	)%	(5,861		)	(8.4	)%
Foreign income tax differential	3,481			6.8	%	(135		)	(0.1	)%	3,412			4.9	%
Stock based compensation	(18,958		)	(37.0	)%	(7,720		)	(9.1	)%	—			—	%
Impact of the Tax Act	3,076			6.0	%	—			—	%	—			—	%
IP installment sale	3,367			6.6	%	—			—	%	—			—	%
Bargain purchase gain	(24,811		)	(48.4	)%	—			—	%	—			—	%
Other	1,720			3.4	%	(653		)	(0.8	)%	107			0.1	%
	$	(17,361	)	(33.8	)%	$	22,080		25.9	%	$	24,714		35.5	%

Deferred tax provision table text block [Table Text Block]

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of our deferred income tax assets (liabilities) are as follows (in thousands):



	December 31,
	2017			2016
Deferred tax asset:
Foreign	$	—		$	1,223
Accruals/other	8,368			857
Acquired future tax deductions	10,580			6,473
Stock-based compensation	8,633			11,089
Foreign currency translation adjustments	3,425			5,175
Tax credits state	8,471			6,764
Foreign tax credits	2,749			—
Inventory reserves	10,658			1,938
Allowance for doubtful accounts	636			151
Valuation allowance	(7,385		)	—
	$	46,135		$	33,670
Deferred tax liability:
State income taxes	$	1,640		$	1,708
Foreign	202			1,370
Depreciation and amortization	21,005			10,027
	$	22,847		$	13,105

Deferred tax asset, net	$	23,288		$	20,565

Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]

The following table summarizes our cumulative gross unrecognized tax benefits (in thousands):



	Year Ended December 31,
	2017			2016			2015
Beginning balance	$	2,000		$	1,772		$	4,115
Increases to prior year tax positions	77			77			25
Increases due to acquisitions	640			—			—
Increases to current year tax positions	3,992			345			345
Decreases to prior year tax positions	(12		)	(46		)	(2,399		)
Decrease related to settlements	—			—			(314		)
Decrease related to lapse of statute of limitations	(170		)	(148		)	—
Ending balance	$	6,527		$	2,000		$	1,772

Market Segments, Geographic Information and Significant Customers Market Segment Breakdown (Tables)

12 Months Ended

Dec. 31, 2017

Market Segment Breakdown [Abstract]

Revenue from External Customers by Products and Services [Table Text Block]

The following table sets forth for the periods indicated, total revenue by product line as a percentage of total revenue:



	Year Ended December 31,
Product line	2017		2016		2015
Infusion Consumables	28	%	86	%	84	%
IV Solutions	40	%	—	%	—	%
Infusion Systems	23	%	—	%	—	%
Critical Care	4	%	14	%	16	%
Other	5	%	—	%	—	%
	100	%	100	%	100	%

Revenue from External Customers by Geographic Areas [Table Text Block]

The table below presents total company revenues, by major country or region (in thousands):



	As of December 31,
	2017		2016		2015
Europe	$	100,423	$	50,105	$	45,062
Canada	69,753		16,266		12,494
LATAM	57,851		29,920		27,780
APAC	54,465		10,304		7,047
Other	30,184		11,083		10,622
Total foreign	$	312,676	$	117,678	$	103,005
United States	979,937		261,694		238,663
Worldwide total	$	1,292,613	$	379,372	$	341,668

Long-lived Assets by Geographic Areas [Table Text Block]

The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):



	As of December 31,
	2017		2016
Costa Rica	$	80,956	$	—
Mexico	61,008		57,971
Other LATAM	19,432		—
Canada	4,362		—
Italy	6,860		4,320
Spain	5,601		—
Other Europe	2,625		966
APAC	5,169		41
Total foreign	$	186,013	$	63,298
United States	422,810		180,657
Worldwide total	$	608,823	$	243,955

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Stockholders' Equity Attributable to Parent [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The components of AOCI, net of tax, were as follows (in thousands):



	Foreign Currency Translation Adjustments			Unrealized Gains on Cash Flow Hedges			Other Adjustments			Total
Balance as of December 31, 2016	$	(21,272	)	$	—		$	—		$	(21,272	)
Other comprehensive income (loss) before reclassifications	6,694			184			(16		)	6,862
Amounts reclassified from AOCI	—			(549		)	—			(549		)
Other comprehensive income (loss)	6,694			(365		)	(16		)	6,313
Balance as of December 31, 2017	$	(14,578	)	$	(365	)	$	(16	)	$	(14,959	)

Commitments and Contingencies Leases (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

As of December 31, 2017, future minimum lease payments under our non-cancelable operating leases are as follows over each of the next five years and thereafter (in millions):



2018	$	8,775
2019	5,907
2020	4,059
2021	3,214
2022	3,105
Thereafter	6,446
Total	$	31,506

Selected Quarterly Financial Data - Unaudited (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Data - Unaudited [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]



	Quarter Ended
	Mar. 31		Jun. 30			Sept. 30		Dec. 31
	(in thousands except per share data)
2017
Total revenue	$	247,739	$	331,514		$	343,236	$	370,124
Gross profit	$	88,945	$	88,062		$	111,598	$	137,490
Net income (loss)	$	55,863	$	(37,060	)	$	136	$	49,705
Net income (loss) per share:
Basic	$	3.03	$	(1.87	)	$	0.01	$	2.47
Diluted	$	2.86	$	(1.87	)	$	0.01	$	2.33
2016
Total revenue	$	89,855	$	96,721		$	97,108	$	95,688
Gross profit	$	49,233	$	50,132		$	51,273	$	50,760
Net income	$	18,160	$	16,606		$	18,806	$	9,512
Net income per share:
Basic	$	1.13	$	1.03		$	1.16	$	0.58
Diluted	$	1.08	$	0.98		$	1.09	$	0.54

______________________________________

On February 3, 2017, we acquired HIS, see Note 2, Acquisitions, Strategic Transaction and Integration Costs.

General and Summary of Significant Accounting Policies Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Raw Materials	$ 82,397	$ 28,435
Work in Process	42,304	4,415
Finished Goods	163,956	16,414
Total	$ 288,657	$ 49,264

General and Summary of Significant Accounting Policies Property and Equipment #1 (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 608,823	$ 243,955
Accumulated Depreciation	210,139	158,259
Net property and equipment	398,684	85,696
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	220,999	96,536
Land, Buildings and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	206,846	63,524
Molds [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	56,253	39,014
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	7,361	3,243
Instruments Placed with Customers [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	15,812	0
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	44,408	26,458
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment, cost	$ 57,144	$ 15,180

General and Summary of Significant Accounting Policies Property and Equipment #2 (Details)	12 Months Ended
	Dec. 31, 2017
Building [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Building [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	30
Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	10
Furniture, fixtures and molds [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	2
Furniture, fixtures and molds [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5
Computer Equipment and Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3
Computer Equipment and Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	5
Instruments Placed with Customers [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3
Instruments Placed with Customers [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	7

General and Summary of Significant Accounting Policies Property and Equipment #3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Depreciation	$ 51.6	$ 16.3	$ 15.9

General and Summary of Significant Accounting Policies Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
GOODWILL	$ 5,577	$ 6,463
Goodwill, Acquired During Period	6,536	0	$ 0
Goodwill, Foreign Currency Translation Gain (Loss)	244
Goodwill, Purchase Accounting Adjustments		(886)
GOODWILL	12,357	$ 5,577	$ 6,463
Fannin [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	1,000
Medical Australia Limited [Member]
Goodwill [Line Items]
Goodwill, Acquired During Period	$ 5,500

General and Summary of Significant Accounting Policies Foreign Currency (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Foreign Currency [Abstract]
Foreign Currency Transaction Gain (Loss), Realized	$ 1.8	$ 0.3	$ 0.2

General and Summary of Significant Accounting Policies Intangible Assets #1 (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 167,044	$ 46,925
Accumulated Amortization	31,516	24,542
Finite-Lived Intangible Assets, Net	135,528	22,383
Intangible Assets, Gross (Excluding Goodwill)	175,269
INTANGIBLE ASSETS, net	$ 143,753	$ 22,383
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	10 years	10 years
Cost	$ 17,064	$ 14,423
Accumulated Amortization	10,970	9,326
Finite-Lived Intangible Assets, Net	$ 6,094	$ 5,097
MCDA contract [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years		10 years
Cost		$ 8,571
Accumulated Amortization		8,571
Finite-Lived Intangible Assets, Net		$ 0
Customer Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	9 years	9 years
Cost	$ 5,319	$ 5,319
Accumulated Amortization	4,892	4,512
Finite-Lived Intangible Assets, Net	$ 427	$ 807
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	9 years	15 years
Cost	$ 55,080	$ 7,080
Accumulated Amortization	6,562	590
Finite-Lived Intangible Assets, Net	$ 48,518	$ 6,490
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	4 years	4 years
Cost	$ 425	$ 425
Accumulated Amortization	425	425
Finite-Lived Intangible Assets, Net	$ 0	$ 0
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	15 years	15 years
Cost	$ 7,310	$ 7,310
Accumulated Amortization	1,096	609
Finite-Lived Intangible Assets, Net	$ 6,214	$ 6,701
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Life in Years	11 years	10 years
Cost	$ 81,846	$ 3,797
Accumulated Amortization	7,571	509
Finite-Lived Intangible Assets, Net	74,275	$ 3,288
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	$ 8,225

General and Summary of Significant Accounting Policies Intangible Assets #2 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Amortization of Intangible Assets	$ 15.0	$ 2.8	$ 2.2

General and Summary of Significant Accounting Policies Future Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 15,996
Finite-Lived Intangible Assets, Amortization Expense, Year Two	15,582
Finite-Lived Intangible Assets, Amortization Expense, Year Three	15,444
Finite-Lived Intangible Assets, Amortization Expense, Year Four	15,361
Finite-Lived Intangible Assets, Amortization Expense, Year Five	15,242
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	57,903
Finite-Lived Intangible Assets, Net	$ 135,528	$ 22,383

General and Summary of Significant Accounting Policies Investments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	$ 24,640
Available-for-sale Securities, Gross Unrealized Gain (Loss)	0
Available-for-sale Securities	$ 24,640
Investment Contract Settlement Date Range End	Jul. 22, 2020
Investment Contract Settlement Date Range Start	Jan. 15, 2018
Long-term Investments [Domain]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	$ 14,579
Available-for-sale Securities, Gross Unrealized Gain (Loss)	0
Available-for-sale Securities	14,579
Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	10,061
Available-for-sale Securities, Gross Unrealized Gain (Loss)	0
Available-for-sale Securities	$ 10,061

General and Summary of Significant Accounting Policies Advertising Expenses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Advertising Expense	$ 0.2	$ 0.1	$ 0.2

General and Summary of Significant Accounting Policies Post-retirement and Post-employment Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Pension and Other Postretirement Benefits Cost (Reversal of Cost)	$ 2.0	$ 1.5	$ 1.3

General and Summary of Significant Accounting Policies Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NET INCOME PER SHARE
Net Income	$ 49,705	$ 136	$ (37,060)	$ 55,863	$ 9,512	$ 18,806	$ 16,606	$ 18,160	$ 68,644	$ 63,084	$ 44,985
Weighted average number of common shares outstanding (basic)									19,614,000	16,168,000	15,848,000
Weighted Average Number Diluted Shares Outstanding Adjustment									1,244,000	1,086,000	648,000
Weighted Average common and common equivalent shares outstandding (diluted)									20,858,000	17,254,000	16,496,000
Basic	$ 2.47	$ 0.01	$ (1.87)	$ 3.03	$ 0.58	$ 1.16	$ 1.03	$ 1.13	$ 3.50	$ 3.90	$ 2.84
Diluted	$ 2.33	$ 0.01	$ (1.87)	$ 2.86	$ 0.54	$ 1.09	$ 0.98	$ 1.08	$ 3.29	$ 3.66	$ 2.73
Weighted Average Number Diluted Shares Outstanding Adjustment										413,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount									337	0	0
Stock Issued During Period, Shares, Acquisitions									3,200,000

General and Summary of Significant Accounting Policies New Accounting Pronouncements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 9.0

Acquisitions and Strategic Transaction Expenses Pro Forma (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$ 1,062
Business Acquisition, Pro Forma Revenue	1,293	$ 180
Business Acquisition, Pro Forma Net Income (Loss)	1,418	$ 22
Fair Value Adjustment to Inventory [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	66,300
Acquisition-related Costs [Member]
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Business Acquisition, Transaction Costs	$ 69,500

Acquisitions and Strategic Transaction Expenses Tangent (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Bargain Purchase Gain	$ 70,890	$ 1,456	$ 0
Tangent [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		2,600
Bargain Purchase Gain		$ 1,500

Acquisitions and Strategic Transaction Expenses EXC (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill, Acquired During Period	$ 6,536	$ 0	$ 0
Liabilities Assumed	$ (156,881)		$ (3,907)
Excelsior [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			14 years
Business Acquisition, Percentage of Voting Interests Acquired			100.00%
Payments to Acquire Business Two, Net of Cash Acquired			$ 56,786
Payments to Acquire Businesses, Gross			59,500
Sale of assets acquired in acquisition			28,970
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			18,076
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets			254
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent			4,426
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			3,982
Goodwill, Acquired During Period			4,985
Liabilities Assumed			(3,907)
Business Combination, Consideration Transferred			$ 56,786
Customer Relationships [Member] \| Excelsior [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			15 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 7,100
Developed Technology Rights [Member] \| Excelsior [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			10 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 3,700
Trade Names [Member] \| Excelsior [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			15 years
Finite-lived Intangible Assets Acquired			$ 7,300

Acquisitions and Strategic Transaction Expenses MLA (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
contingent consideration gross	$ 225.0
Medical Australia Limited [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$ 9.0

Acquisitions and Strategic Transaction Expenses Hospira (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Proceeds from Issuance of Debt	$ 75,000	$ 0	$ 0
Business Combination, Contingent Consideration, Liability, Noncurrent	19,000	0	0
contingent consideration gross	225,000
Issuance of common stock for acquisitions	413,139	0	0
Bargain Purchase Gain	70,890	$ 1,456	$ 0
Hospira [Member]
Business Acquisition [Line Items]
Payment to acquire business, net of working capital adjustments	$ 180,785
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Payments to Acquire Businesses, Gross	$ 260,000
Proceeds from Issuance of Debt	75,000
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 19,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,200
contingent consideration gross	$ 225,000
Earn out Target	$ 1,000,000
Business Acquisition, Share Price	$ 140.75
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 450,400
Discount on equity issued as consideration	37,261
Issuance of common stock for acquisitions	413,139
Business Combination, Consideration Transferred	687,924
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	31,082
Business Combination, Acquired Receivable, Fair Value	362
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	417,622
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets	13,911
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	288,134
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	131,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent	25,080
Bargain Purchase Gain	70,890
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	29,270
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable	12,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other	47,936
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities	67,170
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 783,894
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	9 years
Customer Relationships [Member] \| Hospira [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 48,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	8 years
Pumps and dedicated sets [Domain] \| Hospira [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 44,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
developed technology-consumables [Domain] \| Hospira [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 34,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
In Process Research and Development [Member] \| Hospira [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	$ 5,000
Minimum [Member]
Business Acquisition [Line Items]
Adjusted EBITDA	35,000
Maximum [Member]
Business Acquisition [Line Items]
Adjusted EBITDA	$ 40,000

Acquisitions and Strategic Transaction Expenses Fannin (Details) - Fannin [Member] $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Payments to Acquire Businesses, Gross	$ 1.5

Acquisitions and Strategic Transaction Expenses Strategic Transaction and Integration Expenses - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Strategic Transaction Costs	$ 59.2	$ 14.3	$ 1.8

Restructuring Charges (Details 1) - USD ($) $ in Thousands	12 Months Ended
Restructuring Charges (Details 1) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 800	$ 6,700
Other Restructuring Costs	$ 200
Business Restructuring Reserves [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			4,200
Special Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Buy-out agreement		0
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		$ 600	$ 1,900

Restructuring Charges (Details 2) - USD ($) $ in Thousands	12 Months Ended
Restructuring Charges (Details 2) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 2,029	$ 1,530
Restructuring Charges		800	$ 6,700
Restructuring Costs	18,772	774
Restructuring Reserve, Current	1,290	423	6,539
Payments for Restructuring	(18,256)	(5,869)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		(134)
Restructuring Reserve, Accrual Adjustment	(17)	(48)
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	915	53	2,505
Restructuring Charges		600	1,900
Restructuring Costs	15,983	25
Payments for Restructuring	(15,104)	(2,683)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		(77)
Restructuring Reserve, Accrual Adjustment	(17)	129
government incentive repayment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0	0	1,884
Restructuring Costs	0	0
Payments for Restructuring	0	(1,769)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		(57)
Restructuring Reserve, Accrual Adjustment	0	(172)
Special Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,114	1,477	1,845
Restructuring Costs	0
Buy-out agreement		0
Payments for Restructuring	(363)	(368)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		0
Restructuring Reserve, Accrual Adjustment	0	0
Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0	0	305
Restructuring Costs	0	168
Payments for Restructuring	0	(468)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		0
Restructuring Reserve, Accrual Adjustment	0	(5)
Business Restructuring Reserves [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			4,200
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	0	0	$ 0
Restructuring Charges	2,789	581
Payments for Restructuring	(2,789)	(581)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)		0
Restructuring Reserve, Accrual Adjustment	$ 0	$ 0

Gain on Sale of Building (Details) - USD ($) $ in Thousands	12 Months Ended
Gain on Sale of Building (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Gain on Sale of Building [Abstract]
Selling price of building			$ 3,600
Net Book Value of Building			2,500
Gain (Loss) on Disposition of Assets	$ 0	$ 0	$ 1,086

Legal settlements (Details) - USD ($) $ in Thousands	12 Months Ended
Legal settlements (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Legal Settlements [Abstract]
Legal settlements, including amounts awarded in a dispute and charges/amounts paid out in a separate dispute.	$ 0	$ 0	$ 1,798
Legal settlement charge			6,500
LegalSettlementChargeForLegalFees			700
Payments for Legal Settlements			7,500
Gross legal settlement award			8,800
Legal settlements			$ 5,300

Impairment on assets held for sale (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Impairment of assets held for sale [Abstract]
Impairment of assets held for sale	$ 0	$ 728	$ 4,139
Proceeds from Sale of Buildings		$ 3,300

Share Based Award Stock Based Compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock compensation	$ 19,352	$ 15,242	$ 12,827
Tax benefit from stock-based compensation cost	7,247	5,682	4,922
Indirect tax benefit	1,374	$ 0	$ 1,997
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 23,300
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	10 months

Share Based Award Stock Option Plans (Details) - shares	12 Months Ended
Share Based Award Stock Option Plans (Details) - shares	Dec. 31, 2017	Dec. 31, 2011
2011 Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,925,000	650,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	3,275,000
Shares transferred from superseded plan	263,300.0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	4,188,300
2003 Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	248,700
2001 Director's Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	750,000
Employee Stock Option [Member] \| 2014 Inducement Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	182,366
Restricted Stock Units (RSUs) [Member] \| 2014 Inducement Plan [Member]
Stock Incentive Plans [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	68,039

Share Based Award Stock Options Granted and Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Time-based stock option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	8,825	13,405	22,816
Time based options grant date fair value	$ 375	$ 413	$ 590
Expected term (years)	5 years 6 months	5 years 6 months	5 years 7 months
Expected stock price volatility	27.00%	31.80%	25.90%
Risk-Free Interest Rate	1.10%	0.70%	1.70%
Expected Dividend Yield	0.00%	0.00%	0.00%
Weighted Average Exercise Price	$ 158.20	$ 101.32	$ 93.30
Weighted Average Grant Date Fair Value per option	$ 42.51	$ 30.78	$ 25.86
Performance stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted			244,825
Performance Shares Earned		244,825	349,812
Performance stock options total grant date fair value			$ 6,087
Expected term (years)			3 years
Expected stock price volatility			30.86%
Risk-Free Interest Rate			2.30%
Expected Dividend Yield			0.00%
Weighted Average Exercise Price			$ 91.88
Weighted Average Grant Date Fair Value per option			$ 24.86

Share Based Award Stock Option Activity (Details) - Employee Stock Option [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, Outstanding, Number \| shares	2,018,290
Granted \| shares	8,825
Exercised \| shares	(610,316)
Forfeited or expired \| shares	(72)
Options, Outstanding, Number \| shares	1,416,727
Exercisable \| shares	1,133,734
Vested and Expected to Vest \| shares	1,416,727
Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 58.90
Weighted Average Exercise Price \| $ / shares	158.20
Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	52.43
Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value \| $ / shares	58.79
Options, Outstanding, Weighted Average Exercise Price \| $ / shares	62.30
Exercise Price Range, Exercisable Options, Weighted Average Exercise Price \| $ / shares	60.13
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 62.30
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 9 months
Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 7 months
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	5 years 9 months
Options, Outstanding, Intrinsic Value \| $	$ 217,749
Options, Exercisable, Intrinsic Value \| $	176,721
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 217,749

Share Based Award Share Award data (Details)	Dec. 31, 2017 $ / shares
Share award data [Abstract]
Share Price	$ 216.00

Share Based Award Options exercised data (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Intrinsic value of options exercised	$ 71,283	$ 25,065	$ 28,071
Cash received from exercise of stock options	32,003	17,346	15,042
Tax benefit from stock option exercises	$ 20,004	$ 7,556	$ 9,330

Share Based Award Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock and Performance Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested and expected to vest	159,439
Shares granted	128,364
Change in units due to performance expectations	72,740
Vested	(66,278)
Forfeited	(8,762)
Nonvested and expected to vest	285,503	159,439
Nonvested, Weighted Average Grant Date Fair Value	$ 116.28	$ 84.68
Grants in period, Grant date fair value per share	156.21
Change in units due to performance expectations	86.47
Vested Intrinsic Value, Amount Per Share	80.61
Forfeited, Weighted Average Grant Date Fair Value	$ 148.76
Remaining Contractual Terms	1 year
Aggregate intrinsic value	$ 33,197
Performance Restricted Stock Units (PRSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	20,686	36,370	0
Grants in period, Grant date fair value per share	$ 154.75	$ 86.47	$ 0.00
Grant date fair value performance restricted stock units	$ 3,201	$ 3,145	$ 0
Intrinsic value vested	$ 0	$ 0	$ 787
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Shares Earned	0	0	0
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	107,678	60,377	67,745
Grants in period, Grant date fair value per share	$ 156.49	$ 87.47	$ 93.52
Grant date fair value of restricted stock units granted	$ 16,851	$ 5,281	$ 6,336
Intrinsic value vested	$ 9,813	$ 4,680	$ 2,754

Share Based Award ESPP Narrative (Details)	Dec. 31, 2017 shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
ESPP Original Issuance	750,000
ESPP Annual Issuance Increase Limit	300,000
Shares available in employee stock purchase plan	133,487

Share Based Award ESPP Table (Details) - Employee Stock [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	23,426	31,227	34,299
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 986	$ 955	$ 1,382
Fair Value Assumptions, Expected Term	6 months	6 months	6 months
Expected stock price volatility	28.10%	32.50%	27.00%
Risk-Free Interest Rate	0.60%	0.30%	0.60%
Expected Dividend Yield	0.00%	0.00%	0.00%

Derivatives and Hedging Activities (Details) $ in Millions, $ in Millions	Dec. 31, 2017 USD ($)	Dec. 31, 2017 MXN ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ (0.2)
Derivative, Notional Amount		$ 510.3
Derivative, Forward Exchange Rate	20.01	20.01

Derivatives and Hedging Activities Derivative Balance Sheet Location (Details) - Foreign Exchange Forward [Member] - Designated as Hedging Instrument [Member] $ in Thousands	Dec. 31, 2017 USD ($)
Accrued Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	$ 187
Other Noncurrent Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	402
Derivative Financial Instruments, Liabilities [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability	$ 589

Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative, Gain (Loss) on Derivative, Net	$ 885

Derivatives and Hedging Activities Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - Cash Flow Hedging [Member] - Cost of Sales [Member] - Foreign Exchange Forward [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion	$ 296
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ 885

Fair Value Measurements Fair Value Measurement (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
contingent consideration gross	$ 225

Fair Value Measurements Fair Value Liabilities Measured on Recurring Basis, Unobservable Inputs (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017 USD ($)
Fair Value Disclosures [Abstract]
Contingent Earn-out Liability	$ 0
Acquisition date fair value estimate of earn-out	19,000
Change in fair value of contingent earn-out (included in income from operations as a separate line item)	8,000
Contingent Earn-out Liability	$ 27,000

Fair Value Measurements Fair Value Inputs, Liabilities, Quantitative Information (Details)		12 Months Ended
	Feb. 03, 2017	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Adjusted EBITDA Volatility	29.00%	26.00%
WACC	10.00%	8.75%
20-year risk free rate	2.82%	2.58%
Market price of risk	6.93%	5.99%
Cost of debt	4.16%	4.08%

Fair Value Measurements Fair Value Measurements, Recurring Basis (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Equity Securities, Current	$ 10,061
Available-for-sale Securities, Equity Securities, Noncurrent	14,579
Assets, Fair Value Disclosure, Recurring	24,640
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Equity Securities, Current	0
Available-for-sale Securities, Equity Securities, Noncurrent	0
Assets, Fair Value Disclosure, Recurring	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Equity Securities, Current	10,061
Available-for-sale Securities, Equity Securities, Noncurrent	14,579
Assets, Fair Value Disclosure, Recurring	24,640
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Equity Securities, Current	0
Available-for-sale Securities, Equity Securities, Noncurrent	0
Assets, Fair Value Disclosure, Recurring	0
Earn-out liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	27,000
Earn-out liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	0
Earn-out liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	0
Earn-out liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	27,000
Liabilities, Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	27,589
Liabilities, Total [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	0
Liabilities, Total [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	589
Liabilities, Total [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, Fair Value Disclosure, Recurring	27,000
Accrued Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	187
Accrued Liabilities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0
Accrued Liabilities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	187
Accrued Liabilities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0
Other Noncurrent Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	402
Other Noncurrent Liabilities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	0
Other Noncurrent Liabilities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	402
Other Noncurrent Liabilities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign Currency Contracts, Liability, Fair Value Disclosure	$ 0

Fair Value Measurements Fair Value Nonrecurring Basis (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	$ 12,489
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets Held-for-sale, Long Lived, Fair Value Disclosure	$ 12,489

Prepaids and Other Current Assets Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Prepaid Expense and Other Assets, Current [Abstract]
Deposit Assets	$ 21,940	$ 0
Other Prepaid Expense, Current	4,208	2,948
Prepaid insurance and property taxes	2,580	1,649
Prepaid other taxes	8,097	1,018
Deferred tax charge	1,326	0
Other Assets, Current	3,135	1,740
Prepaid Expense and Other Assets, Current	$ 41,286	$ 7,355

Prepaids and Other Current Assets Related Party (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due from Related Parties, Current	$ 98,807	$ 0
Pfizer MSA Product Costs	72,400
ICU Medical MSA Revenue	70,200
Accounts Receivable [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current	36,425	0
Prepaid Expenses and Other Current Assets [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current	$ 62,382	$ 0
Hospira [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	3,200

Accrued Liabilities an Other Long-term Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities [Abstract]
Salaries and benefits	$ 20,745	$ 5,702
Incentive compensation	40,682	7,912
Accrued Professional Fees	13,319	0
Accrued Product Field Action.	11,810	0
Consigned inventory	5,210	0
Third-party Inventory	4,284	0
Legal accrual	3,538	4,177
Accrued sales taxes	6,291	1,472
Warranties and Returns	3,360	0
Deferred Revenue and Credits, Current	3,326	18
Accrued other taxes	2,771	0
Outside commissions	725	1,141
Accrued freight	5,696	0
Restructuring Reserve, Current	1,290	423	$ 6,539
Acquisition-related accrual	0	2,750
Other	9,017	2,301
Accrued liabilities	$ 132,064	$ 25,896

Accrued Liabilities an Other Long-term Liabilities Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Long-term Liabilities [Abstract]
Contract liabilities	$ 40,148	$ 0
Deferred Revenue, Noncurrent	7,099	0
Benefits	2,104	1,107
Other	5,975	0
OTHER LONG-TERM LIABILITIES	$ 55,326	$ 1,107

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Obligations Credit Facility (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
LOng-Term Obligations Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 150.0
Line of Credit Facility, Remaining Borrowing Capacity	$ 150.0
Line of Credit Facility, Expiration Date	Nov. 08, 2022
Line of Credit Accordion	$ 100.0
Debt Issuance Costs, Line of Credit Arrangements, Gross	$ 1.4
Debt Instrument, Interest Rate Terms	In general, borrowing under the Credit Facility (other than Swingline loans) bears interest, at our option, based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") rate plus applicable margin, as defined below:
Line of Credit Facility, Collateral	Our obligations are secured by: (i) 100% of the equity interests of our guarantor subsidiaries; and (ii) all of the tangible and intangible personal property and assets related to us and our guarantor subsidiaries (including, without limitation, all accounts, equipment, inventory and other goods, all instruments, intellectual property and other general intangibles, deposit accounts, securities accounts and other investment property and cash), and (iii) all products, profits and proceeds of the foregoing. Notwithstanding the foregoing, the collateral shall not include certain excluded property
Line of Credit Facility, Covenant Terms	The Credit Facility contains certain financial covenants pertaining to Consolidated Fixed Charge Coverage and Consolidated Total Leverage Ratios. In addition, the Credit Facility has restrictions pertaining to limitations on debt, liens, negative pledges, loans, advances, acquisitions, other investments, dividends, distributions, redemptions, repurchases of equity interests, fundamental changes and asset sales and other dispositions, prepayments, redemptions and purchases of subordinated debt and other junior debt, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business, fiscal year and accounting practices and amendment of organizational documents and junior debt documents.

Long-Term Obligations Line of Credit Pricing (Details)	12 Months Ended
Long-Term Obligations Line of Credit Pricing (Details)	Dec. 31, 2017
Line of Credit Facility [Line Items]
Debt Instrument, Interest Rate Terms	In general, borrowing under the Credit Facility (other than Swingline loans) bears interest, at our option, based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") rate plus applicable margin, as defined below:
Pricing Level I [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.15%
LIBOR Basis Spread on Variable Rate	1.25%
Debt Instrument, Basis Spread on Variable Rate	0.25%
Pricing Level II [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.20%
LIBOR Basis Spread on Variable Rate	1.50%
Debt Instrument, Basis Spread on Variable Rate	0.50%
Pricing Level III [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.25%
LIBOR Basis Spread on Variable Rate	1.75%
Debt Instrument, Basis Spread on Variable Rate	0.75%
Pricing Level IV [Member] [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Commitment Fee Percentage	0.30%
LIBOR Basis Spread on Variable Rate	2.00%
Debt Instrument, Basis Spread on Variable Rate	1.00%

Long-Term Obligations Senior Note (Details) $ in Millions	Dec. 31, 2017 USD ($)
Long-Term Obligations [Abstract]
Senior Notes	$ 75

Income Taxes Income from continuing operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Foreign Earnings Repatriated	$ 24,000
Income (Loss) from Continuing Operations before Income Taxes, Domestic	59,872	$ 80,714	$ 74,288
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ (8,589)	$ 4,450	$ (4,589)

Income Taxes Provision for income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Current Federal Tax Expense (Benefit)	$ 2,774	$ 21,123	$ 18,601
Current State and Local Tax Expense (Benefit)	2,263	2,347	745
Current Foreign Tax Expense (Benefit)	3,170	1,118	1,426
Current Income Tax Expense (Benefit)	8,207	24,588	20,772
Deferred Federal Income Tax Expense (Benefit)	(20,878)	(2,045)	4,524
Deferred State and Local Income Tax Expense (Benefit)	(4,619)	(767)	(960)
Deferred Foreign Income Tax Expense (Benefit)	(71)	304	378
Deferred Income Tax Expense (Benefit)	(25,568)	(2,508)	3,942
PROVISION FOR INCOME TAXES	$ (17,361)	$ 22,080	$ 24,714

Income Taxes Tax benefit from exercise of stock options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options	$ 20,004	$ 7,556	$ 9,330
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense	$ 7,247	$ 5,682	$ 4,922

Income Taxes Tax Reform (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes Tax Reform (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Foreign Earnings Repatriated	$ 24.0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	35.00%
Income Tax Expense (Benefit)	$ 1.1
RepatriationTollCharge	$ 2.0

Income Taxes Change in taxes payable (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Income Tax Disclosure [Abstract]
Increase (Decrease) in Income Taxes Payable	$ 3.0

Income Taxes Effective tax rate (Details) $ in Thousands	12 Months Ended
Income Taxes Effective tax rate (Details) $ in Thousands	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	$ 51,283	$ 85,164	$ 69,699
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	17,950	29,807	24,395
Income Tax Reconciliation, State and Local Income Taxes	(403)	1,795	2,661
Income Tax Reconciliation, Tax Credits	(2,783)	(1,014)	(5,861)
Income Tax Reconciliation, Foreign Income Tax Rate Differential	$ 3,481	$ (135)	$ 3,412
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	35.00%
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	(0.80%)	2.10%	3.90%
Effective Income Tax Rate Reconciliation, Tax Credits	(5.40%)	(1.20%)	(8.40%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	6.80%	0.10%	(4.90%)
Effective Income Tax Rate, Continuing Operations	(33.80%)	25.90%	35.50%
effective income tax rate reconciliation, ASU 2016-09	$ (18,958)	$ (7,720)	$ 0
effective income tax rate reconciliation-percent, ASU 2016-09	(37.00%)	(9.10%)	(0.00%)
Tax reform	$ 3,076	$ 0	$ 0
EffectiveIncomeTaxRateREconciliationTaxReform	0.060	0.000	0.000
EffectiveIncomeTaxRateReconciliationIPMigration	$ 3,367	$ 0	$ 0
EffectiveTaxRateReconciliationIPMigrationPercent	0.066	0.000	0.000
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$ 1,720	$ (653)	$ 107
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	3.40%	(0.80%)	0.10%
EffectiveIncomeTaxRateReconciliationBargainPurchaseGain	$ (24,811)	$ 0	$ 0
EffectiveTaxRateReconciliationBargainPurchaseGainPercent	(0.484)	0.000	0.000

Income Taxes Deferred income tax provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Components of deferred tax provision [Line Items]
Deferred Income Tax Expense (Benefit)	$ (25,568)	$ (2,508)	$ 3,942

Income Taxes Deferred income tax assets (liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets and liabilities [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	$ 2,749	$ 0
Non-current deferred tax asset	46,135	33,670
Deferred Tax Assets, Net	23,288	20,565
Non-current deferred tax asset, gross total [Member]
Deferred tax assets and liabilities [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	0	1,223
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other	8,368	857
Noncurrent deferred tax asset - acquired future tax deductions	10,580	6,473
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	8,633	11,089
Deferred Tax Assets, Unrealized Currency Losses	3,425	5,175
Noncurrent deferred tax asset - tax credits state	8,471	6,764
Deferred Tax Assets, Inventory	10,658	1,938
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	636	151
Deferred Tax Assets, Valuation Allowance, Noncurrent	(7,385)	0
Noncurrent deferred tax liability [Member]
Deferred tax assets and liabilities [Line Items]
Noncurrent deferred tax liability - depreciation and amortization	21,005	10,027
Noncurrent deferred tax liability - state income taxes	1,640	1,708
Noncurrent deferred tax liability - foreign	202	1,370
Deferred Tax Liabilities, Net	$ 22,847	$ 13,105

Income Taxes Operating Loss Carryforwards (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating loss carryforwards [Abstract]
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options	$ 20,004	$ 7,556	$ 9,330
UNITED STATES
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	4,900
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	6,600
OperatingLossCarryforwardNet	1,100
Operating Loss Carryforwards, Valuation Allowance	$ 5,500

Income Taxes Unrecognized tax benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Unrecognized tax benefits [Abstract]
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions	$ 77	$ 77	$ 25
Unrecognized Tax Benefits, Increase Resulting from Acquisition	640	0	0
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	3,992	345	345
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions	(12)	(46)	(2,399)
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities	0	0	(314)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations	(170)	(148)	0
Unrecognized Tax Benefits	$ 6,527	$ 2,000	$ 1,772	$ 4,115

Income Taxes Tax Carryforwards (Details) $ in Millions	Dec. 31, 2017 USD ($)
CALIFORNIA
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	$ 9.5
UTAH
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	0.3
Foreign Tax Authority [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	$ 2.7

Income Taxes Tax Holiday (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($) $ / shares
Income Tax Holiday [Line Items]
Income Tax Holiday, Aggregate Dollar Amount \| $	$ 5.7
Income Tax Holiday, Income Tax Benefits Per Share \| $ / shares	$ 0.27

Market Segments, Geographic Information and Significant Customers Market Segment Revenue as a % of Total Revenue (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Infusion Consumables [Member]
Market Segment Revenue as a % of Total Revenue [Line Items]
Percent of total revenue	28.00%	86.00%	84.00%
IV Solutions [Member]
Market Segment Revenue as a % of Total Revenue [Line Items]
Percent of total revenue	40.00%	0.00%	0.00%
Infusion Systems [Member]
Market Segment Revenue as a % of Total Revenue [Line Items]
Percent of total revenue	23.00%	0.00%	0.00%
Critical Care [Member]
Market Segment Revenue as a % of Total Revenue [Line Items]
Percent of total revenue	4.00%	14.00%	16.00%
Other Revenue [Member]
Market Segment Revenue as a % of Total Revenue [Line Items]
Percent of total revenue	5.00%	0.00%	0.00%

Market Segments, Geographic Information and Significant Customers Revenue (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Percent of total revenue	76.00%	70.00%	71.00%
International Sales [Domain]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percent of total revenue	24.00%	30.00%	29.00%
Hospira [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration Risk, Percentage		30.00%	36.00%
Hospira [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of total accounts receivable		23.00%

Market Segments, Geographic Information and Significant Customers Revenue by Country (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,292,613,000	$ 379,372,000	$ 341,668,000
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	100,423,000	50,105,000	45,062,000
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	69,753,000	16,266,000	12,494,000
Other LATAM [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	57,851,000	29,920,000	27,780,000
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	54,465,000	10,304,000	7,047,000
Other foreign countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	30,184,000	11,083,000	10,622,000
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	312,676,000	117,678,000	103,005,000
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 979,937,000	$ 261,694,000	$ 238,663,000

Market Segments, Geographic Information and Significant Customers Long Lived Assets by Geographic Location (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 608,823	$ 243,955
COSTA RICA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	80,956	0
Mexico Property and Equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	61,008	57,971
Other LATAM [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	19,432	0
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	4,362	0
Italy Property and Equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	6,860	4,320
SPAIN
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	5,601	0
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	2,625	966
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	5,169	41
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	186,013	63,298
United States property and equipment [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-Lived Assets	$ 422,810	$ 180,657

Stockholders' Equity (Details) - USD ($) $ in Millions	12 Months Ended
Stockholders' Equity (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Equity, Class of Treasury Stock [Line Items]
Treasury stock purchase plan	$ 40.0
Treasury stock purchase plan remaining available	$ 7.2
Stock Repurchased and Retired During Period, Shares		$ 15.4
Shares Paid for Tax Withholding for Share Based Compensation	27,636	20,261
Payments Related to Tax Withholding for Share-based Compensation	$ 4.1	$ 1.9
Treasury Stock, Common, Shares	0	93

Stockholders' Equity Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (21,272)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	6,862
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(549)
Other Comprehensive Income (Loss), Net of Tax	6,313	$ (514)	$ (11,204)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(14,959)	(21,272)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(21,272)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	6,694
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0
Other Comprehensive Income (Loss), Net of Tax	6,694
Accumulated Other Comprehensive Income (Loss), Net of Tax	(14,578)	(21,272)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	0
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	184
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	(549)
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent	(365)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(365)	0
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	0
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	(16)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0
Other Comprehensive Income (Loss), Net of Tax	(16)
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (16)	$ 0

Commitments and Contingencies Lease Commitments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Leases [Abstract]
Operating Leases, Rent Expense	$ 7,900	$ 600	$ 400
Operating Leases, Future Minimum Payments Due, Next Twelve Months	8,775
Operating Leases, Future Minimum Payments, Due in Two Years	5,907
Operating Leases, Future Minimum Payments, Due in Three Years	4,059
Operating Leases, Future Minimum Payments, Due in Four Years	3,214
Operating Leases, Future Minimum Payments, Due in Five Years	3,105
Operating Leases, Future Minimum Payments, Due Thereafter	6,446
Operating Leases, Future Minimum Payments Due	$ 31,506

Commitments and Contingencies Contingencies (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
contingent consideration gross	$ 225

Collaborative and Other Arrangements (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017 USD ($)
Collaborative and Other Arrangements [Abstract]
Fee Cap Six months subsequent to first twelve months	$ 31.3
Transitional Service Agreement Set-up Costs	22.0
Fee Cap - First Twelve Months	$ 62.5

Selected Quarterly Financial Data - Unaudited (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue, Net	$ 370,124	$ 343,236	$ 331,514	$ 247,739	$ 95,688	$ 97,108	$ 96,721	$ 89,855
Gross Profit	137,490	111,598	88,062	88,945	50,760	51,273	50,132	49,233	$ 426,095	$ 201,398	$ 180,797
Net Income	$ 49,705	$ 136	$ (37,060)	$ 55,863	$ 9,512	$ 18,806	$ 16,606	$ 18,160	$ 68,644	$ 63,084	$ 44,985
Basic	$ 2.47	$ 0.01	$ (1.87)	$ 3.03	$ 0.58	$ 1.16	$ 1.03	$ 1.13	$ 3.50	$ 3.90	$ 2.84
Diluted	$ 2.33	$ 0.01	$ (1.87)	$ 2.86	$ 0.54	$ 1.09	$ 0.98	$ 1.08	$ 3.29	$ 3.66	$ 2.73